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Background: Gene expression can be altered in a number of ways, such as modifying 
chromatin; the packaged form of DNA, with one method being histone modifications. 
Histones are proteins, which along with DNA form the nucleosome; the repeating structure 
of chromatin. Amongst the methods of modifying histones is acetylation and deacetylation, 
which is carried out by histone acetylases (HATS) and histone deacetylases (HDACs). HDACs 
however, can be inhibited by a number of agents, including valproic acid (VPA) and 
trichostatin A (TSA). Such post-translational modifications can affect gene expression and as 
such it is hypothesised that epigenetic effects caused by HDACi’s may be heritable. 
Aims: To investigate whether the HDACi’s VPA and TSA induce changes in Hox B gene 
expression in differentiating embryonic stem cells and whether this gene expression change 
is heritable, through the use of cell culture and Real Time PCR. 
Results: No VPA induced effect was observed for the majority of the Hox B gene cluster. 
However, when ESCs were differentiated for a longer time period VPA induced a heritable 
increase in Hox B5 gene expression, which was maintained for 72 hours. However, this effect 
was not seen using TSA but continuous TSA application may induce Hox B2 expression. TSA 
also reduced the number and size of differentiating embryoid bodies.  
Conclusion: The VPA induced Hox B5 gene expression increase provides a proof of concept 
for epigenetic heritability but further work is required to confirm this finding and expand the 
knowledge  Within the field of epigenetic heritability.








Genetic change is usually inherited through DNA sequence modification, however it has 
been proposed that epigenetics may also cause heritable changes to genomic DNA [2, 3], 
through post-translational modifications affecting chromatin structure. One factor 
influencing such changes is the environment and agents within this environment may cause 
heritable changes through mitosis [2].One set of post-translational modifications involves 
the regulation of histone acetylation, which can be utilised to study the heritability of 
epigenetic effects [3]. With this concept outlined below.  
1.1 Control of Gene Expression  
It is vital for multicellular organisms to regulate gene expression; otherwise each cell would 
express all of the organism’s genes at the same time. In such a scenario each cell of the 
organism would be phenotypically identical and specialised cells would not be apparent. 
However, this is not the case as specialised cells only expresses the genes required for the 
cell to undertake its specific function. This is due to control of gene expression, which is 
widely documented and occurs at many levels, from transcription to translation and post-
translational modifications [4]. Transcription factors bind to promoters and allow gene 
transcription but access has to be available to the required part of the genome. Involved in 











1.2 Chromatin Structure 
Chromatin is the packaged form of DNA, contained with the nucleus and is a product of both 
DNA and protein [1]. The basic structure is a repeating unit known as a nucleosome. 
Structurally the nucleosome is comprised of eight histones (a histone octamer) and DNA [5]. 
Histones are a family of proteins with 5 major groups: H1/H5, H2A, H2B, H3 and H4 [6]. The 
histone octamer contains two of histone H2A, H2B, H3 and H4, known as core histones [5, 7] 
which project an N-terminal tail outwards and are accessible to post-translational 
modifications [8]. The linker histones, H1 and H5, also undergo post-translational 
modifications. 145-147 bp’s of DNA wraps around the octamer core in 1.65 helical turns [5, 
7]. In between each nucleosome is a linker strand of DNA (50bp) producing the 10nm fibre (a 
‘beads on a string’ structure) [9], (figure 1.1) [1]. This basic structure is further compacted 
(with the aid of histone H1) to produce the 30nm fiber [10], which following additional 
folding forms the 300nm extended scaffold [11] and condenses to produce the 700 nm 
scaffold [1]. The highest level of compaction of chromatin is the 1400nm metaphase 
chromosome, which is easily observed by the light microscope in metaphase. Although 
highly structural the nucleosome also acts as a signalling molecule, through chromatin 
modification [3].    
  








Figure 1.1 Diagrammatic representation of chromatin folding  
DNA double strand coils around a histone octamer to produce a 
nucleosome which generates a ’beads on a string’ structure. Further 
folding produces a 30nm chromatin fiber, followed by a 300nm extended 
scaffold and a 700 nm condensed scaffold. With the most condense form 
being the 1400nm metaphase chromosome [1].  







1.2.1 Chromatin Modifications 
Chromatin structure can be modified in three main ways: either DNA methylation, histone 
variants or core histone post-translational modifications [12]. To date the different 
categories of post-translational histone modification are; acetylation, methylation, 
phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, deimination, proline 
isomerisation and histone tail clipping [13, 14]. This field is extensive and research has 
identified of 100+ histone residue modification sites [15]. Histone modification is brought 
about via enzyme families, with each modification having specific enzymes to add and 
remove a particular modification. Such as kinases adding phosphate and phosphatases 
removing phosphate (figure 1.2). In addition, a balance between opposing enzymes is 
obtained so histone modification is regulated. 
1.2.2 Histone Acetylation, deacetylation and inhibition 
Acetylation of histones was first published in 1964 and occurs on lysine residues of the N-
terminal tails of core histones [16]. With acetylation carried out by histone 
acetyltransferases (HATs) and deacetylation by their counterparts: histone deacetylases 
(HDACs), shown in figure 1.2 [14]. HATs utilise acetyl CoA as a cofactor to add the acetyl 
group on lysine, a process associated with transcriptional activation [17]. HATs have two 
major classes; type-A and type B [14], whereas HDACs have four major classes; classes I-IV 
[18], with class II subdivided into a and b [17]. HDAC’s tend to be less specific and will bind 
and deacetylate various different sites [14]. HDACs vary in length from 310aa-1215aa and 
cellular localization [17].  As is the case with many enzymes they can be inhibited and such 
molecules are termed HDAC inhibitors (HDACi). HDACi’s are classified into; benzamides, 







short chain fatty acids, cyclic tetrapeptides, hydroxamic acids, cyclic peptides, psammaplins 
and epoxides [17].  
Amongst the short fatty acids is valproic acid (VPA) [19] which inhibits class I and IIa HDAC’s 
when applied in the millimolar range [20, 21]. Within the hydroxamic acids is trichostatin A 
(TSA) [22], which also inhibits class I and class II HDACs, although at a lower concentration, 
within the nanomolar range [17]. 
  
Figure 1.2 Diagramatic representation of Histone modification 
Adipogenic enzymatic enzyme pairs which modify core histones; 
methylation (methylase) and demethylation, (demethylase) 
phosphorylation (kinase) and dephosporylation  (phosphatase), acetylation 
(acetylase) and deacetylation (deacetylase).  Also displayed are two types 
of histone deacetylases (HDAC) inhibitors; short chain fatty acids such as 
valproic acid (VPA) and hydroxamic acid derivatives, i.e. Trichostatin A 
(TSA). Modified from Turner (2009)[2] 
 
 







1.3 Histone Code 
With many categories and sites of histone modifications discovered, it has led to the 
hypothesis of a Histone code [23]. With the proposition for a code to exist requiring a 
number of prerequisites: that histone modifications bind to specific partners, there is a 
pattern of heritability and that modifications combine to form patterns [15]. Although there 
is much debate whether a code does exist, with some arguing a more appropriate code is an 
‘epigenetic code’ [24]. Such a code focuses on determining the long term and heritable 
effects of histone modifications and whether it would allow prediction of an outcome (gene 
expression levels), provided with just the modifications [24].  Whether such codes exist may 
be elucidated in the future, once ‘all’ histone modifications and their outcomes have been 
ascertained.  
1.4 Epigenetic Heritability 
Epigenetics is the field of studying changes in gene expression not brought about via the 
DNA sequence [25] and was first coined by Conrad Waddington. With particular interest on 
whether these changes are heritable through mitosis. For epigenetic heritability to occur 
chromatin structure must be altered resulting in observable genetic alteration, such as 
changing gene expression levels. This change would be observed following removal of the 
inducing agent and inherited by future cellular generations via mitosis [2]. Within epigenetic 
heritability the environment has been implemented, as it could provide the modifying agent, 
such as VPA inhibiting HDACs and effecting histone acetylation [2]. A proof of concept of 
epigenetic heritability is provided through X inactivation and in a model utilising Hox B gene 
cluster expression in embryonic stem cells, in response to VPA [26]. Although further study is 
required to determine the extent epigenetic modifications are heritable.  







1.5 Hox Genes Cluster 
Throughout embryological development there is requirement for an organised system 
regulating translation, so development occurs in an established order [27]. One system first 
observed and described in Drosophila [28] is the Hox gene cluster, which regulates basic 
orientation [29]. Vertebrates contain four Hox or homeobox gene clusters, termed Hox A – D 
[27, 29, 30] and mammals have 39 genes spread over the four clusters [27]. Functionally, it is 
proposed expression of particular Hox gene proteins specifies positional identity [29]. The 
mammalian Hox B cluster is comprised of Hox B1-B9 and Hox B13 [31]. In terms of regulating 
hox genes, retinoic acid (RA) is involved, which functions through retinoic acid receptors 
(RARs) [29]. RA is a vitamin A derivate [32, 33] involved in regulating Hox gene induced CNS 
patterning [34]. RA induces Hox gene expression in a manner relating to the organisation of 
the Hox gene cluster [35], 3’ Hox B1 is induced first, as it contains a retinoic acid responsive 
element (RARE) [29, 33] [36] Hox A1 [37], Hox A4 [38] and Hox D4 [39, 40] also contain 
RARES with Hox B1 and B3-B5 being RA sensitive [41].  
1.6 Embryonic Stem Cells 
Post fertilization the zygote undergoes mitosis to produce a morula which develops into a 
blastocyst [42]. The blastocyst is comprised of an outer layer and an inner cell mass (ICM), 
the source of embryonic stem cells (ESC) [43]. ESCs are pluripotent [44], having the ability to 
differentiate into specialised cells developed from the three germ layers, but are unable to 
produce non foetal tissue (i.e. placenta) [45]. In addition ESCs can self-renew, that is divide 
indefinitely into ESCs, which are pluripotent and undifferentiated [44]. To confirm the  
pluripotency of ESC’s a number of markers can be utilised, such as Oct4 [46] and Nanog [47]. 
Oct 4 being a transcription factor encoded by the Pou5f1 gene [48] and Nanog a DNA 







binding homeoprotein [47]. Both maintain pluripotency [47-49] as does LIF (leukaemia 
inhibiting factor) application [50].    
1.7 Aims 
The purpose of this study is to investigate whether epigenetic changes are heritable, using a 
model of HDACi on Hox B gene expression in differentiating ESCs. Do HDACi induce changes 




















2 Materials and Methods 
2.1 Cell Culture 
2.1.1 Undifferentiated CCER’s 
CCE/Rs, a male mouse embryonic stem cell line were used as a model ES cell. 
Undifferentiated ES cells were cultured in 0.1% gelatinised T25/T75 cm2 flasks (Sarstedt) and 
incubated at 37°C in 5% CO2, with Dulbecco’s modified eagle medium (DMEM, Gibco).  
DMEM supplemented with 20% Foetal Calf/Bovine Serum (Gibco), 10% pure sterile water, 
1% L-glutamine (Gibco), 1% Penicillin/Streptomycin, 1% non-essential amino acids (Gibco), 
0.25% 2-mercaptoethanol and LIF (Chemicon) at 1µl/10ml medium.  
ES cells passaged every other day when ~70% using trypsin-EDTA 1X preheated to 37°C 
(Gibco). Supplemented DMEM removed and cells suspended with trypsin EDTA 1X, followed 
by trypsin inactivation with the addition of the removed DMEM. Cell suspension centrifuged 
(5 minutes, 1000rpm) and pelleted, with removal of media/trypsin supernatant. ESCs re-
suspended in fresh DMEM (37°C) in a 1:4 - 1:6 ratio to new flasks (pre-treated with 0.1% 
gelatine for 20 minutes). Media replaced on alternative days.    
2.1.2 Differentiation of CCER’s  
ESCs were passaged as normal but re-suspended in supplemented DMEM but without LIF, 
before plating onto non-adherent petri dishes (Sterilin), with embryoid bodies being cultured 
with supplemented DMEM (without LIF). On day two 1µM Retinoic Acid (RA) added to 
induce Homeobox (Hox) gene expression and maintained throughout differentiation period.  
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2.1.3 HDACi Treatment 
Differentiated embryoid bodies were treated with 1mM Valproic acid (VPA), either 16 or 72 
hours after RA addition [51]. VPA was removed from Embryoid bodies after 8 hours. Petri 
dishes placed at an angle to allow suspended embryoid bodies to accumulate towards the 
bottom, media gently removed without removing embryoid bodies. Fresh supplemented 
DMEM (37°C, -LIF, +RA) added to embryoid bodies before careful removal and the addition 
of supplemented DMEM (37°C, -LIF, +RA). Embryoid bodies were incubated at 37°C and 5% 
CO2.  Media was replaced every 1-2 days as required, using same methodology but 
supplemented DMEM (37°C, -LIF, +RA) added once.  
 Trichostatin A (TSA) added at 10ng/ml 16 hours after RA treatment. With either removal 
after 8 hours or continuous treatment (figure 3.1C). Same wash out and media replacement 
method as VPA.  
2.2 Gene Transcription Analysis 
2.2.1 RNA Extraction 
ESCs were trysinised and centrifuged as before, with supernatant discarded. Embryoid 
bodies were centrifuged (5 minutes, 1000rpm). ESC and embryoid cell pellets were re-
suspended in 1X PBS and centrifuged (1000rpm, 5 minutes, 4°C) twice, supernatant 
discarded each time. Cell pellet homogenised with 2ml syringe and needle in 350µl RLT lysis 
buffer from RNeasy mini kit (Qiagen) and frozen until required.  
RNA extracted using the RNeasy Mini kit (Qiagen) following the protocol for ‘Purification of 
total RNA from animal cells using spin technology’. Briefly 350μl 70% ethanol added to 350μl 
RLT lysis buffer cell suspension and centrifuged (15s, 13,300rpm) in a spin column. Flow 
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though discarded. Spin column washed and centrifuged (15s, 13,300rpm) with 700μl of RW1, 
followed by 500μl RPE, with flow through discarded each time. Spin column washed and 
centrifuged (2 minutes, 13,300rpm) with RPE. RNA eluted with 40μl RNase free water by 
centrifugation (1 minute, 13,300rpm).    
2.2.2 RNA Quantification & Integrity 
RNA concentration determined using a Nanodrop ND1000 Spectrophotometer. Device 
blanked with 1.2μl water and 1.2μl of sample used to determine RNA concentration (ng/μl) 
and the 260/280 (Nucleic acid/protein) ratio. 
RNA integrity confirmed by running 1 µg RNA sample on a 1% agarose gel. 1% agarose in 1X 
TAE buffer (40mM Tris base, 1.142% (v/v) glacial acetic acid, 1mM EDTA pH 8) with 0.5µg/ml 
ethidium bromide. Agarose gel run at 60V for 1-1.5 hours with 18S and 28S ribosomal RNA 
banding detected. Image obtained using Syngene imager. 
2.2.3 cDNA Synthesis 
RNA was transcribed into cDNA using Superscript III Reverse Transcriptase (Invitrogen). 2μg 
RNA incubated at 65°C for 5 minutes along with 1µl Oligo dT and 1µl dNTP mix, in a total 
reaction volume of 13µl. Followed by 1 minute on ice. 4µl 5X First Strand Buffer, 1µl 0.1M 
DTT, 1µl RNase Inhibitor and 1µl Superscript Reverse Transcriptase added to sample before 
incubation at 50°C for 60 minutes followed by 70°C for 15 minutes.  
2.2.4 DNA Quantification and Integrity 
cDNA was quantified using a Nanodrop ND1000 spectrophotometer, device blanked with 
1.2μl water and 1.2μl of sample used to determine concentration (ng/ml) and 260/230 
(nucleic acid/polysaccharide) and 260/280 (nucleic acid/protein) ratios. Samples diluted 1:10 
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and as required to produce 10ng/ml solution. Integrity confirmed with GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) PCR using ReddyMix 1.1X (Invitrogen), as per 
manufacturer’s instructions. Reddymix containing dNTPs, DNA polymerase, 1.5mM MgCl2, 
reaction buffer and gel loading dye. 10 ng cDNA cycled with 0.25μl GAPDH forward primer, 
0.25μl GAPDH reverse primer, 1.5μl water and 22.5μl ReddyMix master mix. PCR cycle 
below: 
94°C – 1 minute 
60°C – 1 minute 30 Cycles 
72°C – 1.5 minutes 
10°C - hold 
10μl of PCR product run with 2μl 6X DNA loading dye on 1% agarose gel electrophoresis for 
~45 minutes at 60V. Along with 10μl of 100bp DNA ladder.  Image obtained on Syngene 
imager, with bands to confirm cDNA quality.  
2.2.5 RTQ-PCR 
Quantitative real time PCR was utilised to determine the relative expression of Hox B genes 
against GAPDH expression. The dye SYBR Green (Qiagen) was used, which absorbs light at 
488nm and emits light at 522nm. SYBR green fluoresces when bound to DNA so fluorescence 
intensity will increase as the PCR cycle number increases, which is measurable.  
Reaction mixes contained 10 ng of sample cDNA, 0.25μl forward primer, 0.25μl reverse 
primer, 4μl SYBR and 4μl water for a total volume of 10μl. Hox B1-Hox B9, GAPDH, Pou5f1 
and Nanog gene expression was investigated, with primers in table 2.1. Each primer pair run 
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as technical triplicates, on a 384 well plate. Water replaced 10ng samples as a non-loading 
control.  
RTQ-PCR processed by ABI 7900HT thermocycler with absolute quantification determined 
and reporter as SYBR non fluorescent quencher. Cycle conditions below; 
Stage 1 95°C for 10 minutes 
Stage 2 95°C for 15 seconds 
60°C for 15 seconds  40 cycles 
72°C for 30 seconds 
Stage 3 95°C dissociation curve.  
Data collected at 72°C in stage 2. Each sample gave an amplification curve and Ct (threshold 
cycle) number, which is the PCR cycle number when a threshold fluorescence value is 
reached. Lower Ct values due to an increased amount of cDNA. Threshold value was 
confirmed to be within the exponential phase of the amplification curve.  
Formula applied to Ct data to remove undetermined and outlying data (>0.7 Ct value 
variation) and calculate the mean and SEM. Data normalised against GAPDH expression to 
give ΔCt and relative expression determined as 2-ΔCt. Results plotted graphically against 
relative expression to GAPDH, along with SEM.   
Due to the exploratory nature of the experiments and lack of definite hypothesis no 
statistical analysis was undertaken. Also due to the fact sample size in all experiments was 1 
and the repeats to obtain the SEM where technical replicates and not biological. 
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Furthermore parametic tests require and assumption of normal distribution which is in 
appropriate for this data set [52, 53].  
2.3 Image Analysis 
Light microscopy images obtained using a Canon Eos 600D SLR and manipulated using Image 
J. The 2D area of 15 embryoid bodies were mapped and averaged produce an arbitrary 
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Gene Forward Primer Reverse Primer 
GAPDH CGGCCGCATCTTCTTGTGCA AGTGGGGTCTCGCTCCTGGA 
Pou5f1 GAGGAGTCCCAGGACATGAA AGATGGTGGTCTGGCTGAAC 
Nanog CTCATCAATGCCTGCAGTTTTTCA CTCCTCAGGGCCCTTGTCAGC 
Hox B1 CCATATCCTCCGCCGCAG CGGACTGGTCAGAGGCATC 
Hox B2 CGGCGCCTCCACCCTTCAGAGACC CTTTCGGTGAGGTCCAGCAAGGC 
Hox B3 CAACTCCACCCTCACCAAA GCCACCACCACAACCTTC 
Hox B4 CTGGATGCGCAAAGTTCAC TCCTTCTCCAACTCCAGGAC 
Hox B5 CCTCTGAGCCCGAGGAAG CCAGGGTCTGGTAGCGAGTA 
Hox B6 GAGACCGAGGAGCAGAAGTG ACTGAGCTGAGACGCACTGA 
Hox B7 AACCGAGTTCCTTCAACATG CGAGTCAGGTAGCGATTGTA 
Hox B8 TTCTACGGCTACGACCCTCT CGTGCGATACCTCGATCCTC 
Hox B9 CAGGGAGGCTGTCCTGTCTAATC CTTCTCTAGCTCCAGCGTCTGG 
Table 2.1 Gene expression primers used for PCR and RTQ-PCR 
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3.1 VPA differentiation protocol 
To determine if HDACi’s induced heritable epigenetic changes a model system utilising 
differentiating ESCs was produced (figure 3.1). Undifferentiated ESC’s were seeded on day 0, 
coinciding with LIF removal. On day 2 RA was added to stimulate differentiation, followed 16 
hours later (day 3) by VPA addition (8hrs) or omission.  After 8 hours VPA was removed and 
samples harvested for RNA extraction and cDNA analysis. To investigate heritability after 
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VPA removal samples were maintained and harvested at 24 hour intervals. 
 
 








+ RA  
- VPA   
+ VPA  
(8 Hours)  
  Wash 
Out 
  Harvest  
  Harvest  
  Harvest  
  Harvest  
  Harvest  









 - LIF 
 
16 hours  
Undifferentiated ESC’s  seeded on day 0, alongside LIF removal  RA added on day 2, 
followed 16 hours later by VPA addition or omission (day 3~). After 8 hours VPA 
removed where appropriate, and samples harvested for later analysis. On occasion 
protocol extended until day 8. Samples harvested at 24 hour intervals. 
Figure 3.1: Displaying the differentiation protocol utilised to provide a 
ESC model for investigating epigenetic heritability 
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3.2 HDACi VPA does not affect Pou5f1 expression in differentiating ESC’s 
and RA addition aids differentiation 
Prior to investigating HDACi’s on Hox B gene expression the differentiation protocol required 
confirmation that ESC’s differentiated, so Pouf51 expression was determined with HDACi 
VPA. Undifferentiated ESCs were harvested on day 0 to compare against differentiating ESC’s 
(protocol in figure 3.1). VPA was added 16 hours later for 8 hours (D3+). Following the 8 hour 
incubation one sample had VPA removed and harvested immediately (D3+), with another 24 
hours later (D4 WO). Harvested samples were analysed for Pou5f1 gene expression via qRT-
PCR with data normalised to GAPDH expression.  As expected Pou5f1 expression was high in 
undifferentiated cells on day 0 (figure 3.2A) and decreased by ~90.3% by day 2 and as such 
LIF removal induced ESC differentiation. Pou5f1 expression was maintained at low levels 
following RA addition, decreasing further on day 3 and day 4 (figure 3.2A). VPA had no effect 
on Pou5f1 expression as samples treated with VPA maintained low expression levels (figure 
3.2A). Thus the differentiation protocol induced ESC differentiation. Furthermore, Nanog 
expression displayed a similar effect, decreasing throughout differentiation (data not 
shown).  
To confirm that ESCs maintained their differentiated state the protocol was repeated with 
cells cultured until day 8. Pou5f1 expression decreased throughout the culture period, from 
day 2 until day 8 (figure 3.2B) and ESCs remained differentiated. Expression levels in 
undifferentiated cells (day 0) was higher than differentiating ESCs (D2-D8), but not to the 
extent previously recorded (figure 3.2A). VPA had no effect on gene expression.  
To confirm this finding Pou5f1 expression was analysed in ESCs differentiating for a longer 
period (protocol figure 3.5). In addition, the effect of RA inducing differentiation was 
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investigated, by omitting RA. Undifferentiated ESC’s were seeded on day 0 with LIF removal. 
RA was added (+RA) or omitted (-RA) on day 2 followed by VPA application (8 hours) (D5+) or 
omission on day 5. Following 8 hours of VPA samples were either immediately harvested 
(D5+) or VPA washed out and harvested 24 hours later (D6WO). Again Pou5f1 expression in 
undifferentiated cells (D0) was high and expression decreased by day 2 (figure 3.2C). Pou5f1 
expression was reduced in day 5 and day 6 samples, in comparison to D0. However, Pou5f1 
expression in samples without RA was higher than those with RA (compare both D5- values). 
As such differentiated ESC’s lacking RA are not as differentiated as those in contact with RA 
(figure 3.2C). VPA did not affect Pou5f1 expression.  
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Figure 3.2: Effect of VPA on Pou5f1 gene expression in differentiating 
ESC’s. 
Log of Pou5f1 expression relative to GAPDH expression in undifferentiated 
(D0) and differentiating ESCs (D2-D4). (A) addition of VPA (1mM) on D3 for 
8hrs (D3+) before VPA removal and incubation for 24hrs (D4 WO) (B) Addition 
of VPA  (1mM) on D3 for 8hrs (3+) before VPA removal and incubation until 
Day 8. Samples harvested at 24hr intervals (4WO, 5WO, 6WO, 7 WO, 8WO). (C) 
Differentiated ESCs (D2-D6) compared -/+ RA, and -/+ VPA (1mM) for 8hrs 
before VPA removal and incubating for a further 24hrs (WO) (n=3 -/+SEM of 





- RA + RA 
Hox Gene Expression in mouse Embryonic Stem Cells 
August 2012 
 




3.3 VPA increases Hox B1 expression  
Once the differentiation protocol was confirmed as valid, the effect of VPA on Hox B gene 
expression was investigated. The mouse Hox B gene cluster consists of 10 elements, Hox B1- 
Hox B9 and Hox B13 (figure 3.3A). Experimental methodology followed the differentiation 
protocol in figure 3.1 until day 3. Undifferentiated ESCs seeded on day 0 with LIF removal 
and RA addition on day 2. VPA (1mM) was added on day 3 (D3+) for 8 hours followed by 
sample harvesting and Hox B gene expression analysis. No Hox B gene expression was 
observed in undifferentiated cells (D0) or day 2 differentiated samples (figure 3.3B). After 16 
hours of RA Hox B1 was expressed on day 3 (D3-) and the 8 hour VPA (1mM) treatment 
increased expression ~ 2 fold (D3+). The rest of the Hox B genes showed little expression and 
VPA had no effect (figure 3.3B). Pou5f1 expression decreased throughout differentiation 
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Figure 3.3 Effect of VPA on Hox B gene expression in differentiating ESC’s 
Log of expression of Hox B1-B9 relative to GAPDH expression in undifferentiated (DO) 
and differentiating ESC’s (D2 & D3). (A) Diagramatic representation of the mouse Hox B 
gene cluster. (B) VPA addition (1mM) on D3 for 8 hrs (D3+) before VPA removal and 
immediate sample harvesting. (n=3 -/+SEM of three technical replicates) 
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3.4 Effect of VPA on Hox B1 and Hox B9 is not heritable.  
To determine if VPA induced a heritable effect on Hox gene expression the differentiation 
protocol was extended to day 4. As the majority of Hox B genes displayed low levels of 
expression (figure 3.3) only those with higher levels were tested, Hox B1 and Hox B9. 
Experimental protocol as before but following VPA removal (D3+), a group of samples were 
incubated for 24 hours before harvesting (D4 WO). Both Hox B1 and Hox B9 displayed very 
little or no expression in undifferentiated D0 cells (figure 3.4A and 3.4B, respectively). Hox 
B1 displayed very little expression on Day 2 of differentiation, whereas Hox B9 expression 
was detected. The previous (figure 3.3) VPA induced increase in Hox B1 gene expression was 
not observed, with VPA not effecting expression levels on  day 3 nor day 4 (figure 3.4A). In 
individual experiments both an increase and decrease was detected on day 3, comparing 
VPA (D3+) samples to control samples (D3-) (individual experimental data not shown). 
However, VPA decreased Hox B9 expression on day 3 but this effect was not heritable (figure 
3.4B). Pou5f1 expression decreased throughout differentiation and was not affected by VPA 
(data not shown).  
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Figure 3.4 Effect of VPA on Hox B1 and Hox B9 heritable gene 
expression in differentiating ESC’s 
Log of Hox B1 and Hox B9 gene expression relative to GAPDH expression in 
undifferentiated (D0) and differentiating ESC’s (D3-D4). Addition of VPA (1mM) 
on D3 for 8 hrs (D3+) before VPA removal and incubation for 24 hrs (D4 WO) (A) 
Hox B1 Expression (n=6 -/+SEM for triplicate replicates of 2 separate 
experiments) (B) Hox B9 Expression. (n=3 -/+SEM for three technical replicates.  
A 
B 
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3.5 Longer Differentiation Protocol 
Following on from the previous protocol the differentiation period was increased and RA 
addition was investigated (figure 3.5). Undifferentiated ESCs were seeded on day 0 with LIF 
removal. RA was either added or omitted on day 2 and cell culture maintained.  On day 5 
VPA (1mM) was added (8 hours) or omitted to both sets of samples, those with and without 
RA. Following VPA removal samples were immediately harvested (D5+) or incubated for 24 
hours and harvested (D6WO).  
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Figure 3.5 Longer differentiation protocol 
With the effect of RA on differentiation. Undifferentiated ESCs seeded on day 0 
alongside LIF removal. On day 2 RA addition or omission. On day 5 VPA addition (8 
hours) or omission to samples with and without RA. Followed by VPA removal 
where required. Samples harvested on day 5 and 24 hours later on day 6. 
  
Harvest   
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3.6 VPA induces a heritable Hox B5 gene expression increase    
No heritable effect was observed for Hox B1 or Hox B9 in the first differentiation protocol so 
the effect of VPA was investigated using a longer differentiation protocol (figure 3.5). Hox B1 
and Hox B9 were studied along with Hox B3 and Hox B5, both sensitive to RA [41]. The 
protocol also determined the effect of RA on differentiation and Hox B gene expression. 
Undifferentiated ESC’s seeded on day 0 coinciding with LIF removal, followed by RA addition 
on day 2 (+RA) or omission (-RA). VPA (1mM) was added on day 5 (D5+) for 8 hours, to both 
RA conditions. VPA removed and samples immediately harvested (D5+) or incubated and 
harvested 24 hours later (D6 WO). Hox B1, Hox B3, Hox B5 and Hox B9 expression was not 
detected in undifferentiated ESC’s (D0) nor on day 2 (D2) (figure 3.6). Expression was not 
detected or very low in samples lacking RA (-RA). No difference between control samples 
and VPA treated samples was detected on day 5 for Hox B5 gene expression. However, 24 
hours after VPA removal, Hox B5 gene expression was increased (+RA D6 WO) in comparison 
to control (+RA D6-) (figure 3.6A). Thus displaying a heritable epigenetic change in Hox B5 
gene expression in differentiating ESC’s, induced by VPA (1mM). This trend was observed for 
Hox B9 expression at lower levels, a ~10 fold decrease in expression levels when compared 
to Hox B5 (figure 3.6B), noted by the scaling. Hox B1 expression was low and undetermined 
on +RA D6 WO and Hox B3 displayed no expression (data not shown).   
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Figure 3.6 Effect of RA and VPA on Hox B5 and Hox B9 gene 
expression in differentiating ESC’s.  
Log of Hox B5 and Hox B9 expression relative to GAPDH in undifferentiated 
(D0) and differentiating ESCs (D2-D6). Differentiated ESCs compared -/+ RA 
and -/+ VPA (1mM) for 8 hrs, before removal and immediate harvesting 
(D5+)  or 24 incubation (D6 WO). (A) Hox B5 gene expression (B) Hox B9 
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3.7 VPA induces a heritable Hox B5 gene expression increase for 72 hours 
VPA induced a heritable Hox B5 gene expression increase (figure 3.6). As Hox B5 displayed 
expression after longer differentiation the original differentiation protocol, (figure 3.1) was 
extended until day 8, to determine if Hox B5 expression occurred at a later stage of  
differentiation. Hox B1, Hox B3 and Hox B9 expression was also evaluated. Undifferentiated 
ESC’s seeded (D0) and LIF removed followed by RA on day 2. 16 hours later VPA addition for 
8 hours (D3+). Following VPA removal samples were immediately harvested (D3+) or 
incubated and harvested at 24 hour intervals (D4-D8 WO). Hox B1, Hox B3, Hox B5 and Hox 
B9 expression was not observed in undifferentiated ESC’s (D0) or in day 2 differentiating 
ESC’s (figure 3.7, Hox B1 and Hox B3 data not presented). Hox B5 gene expression decreased 
under VPA treatment (D3+). However, following VPA removal Hox B5 expression increased 
for 72 hours (D4-D6 WO) in comparison controls (D4-D6-) (figure 3.7A). By day 7 and 8 Hox 
B5 gene expression in VPA treated (D7WO and D8WO) samples was lower than VPA lacking 
samples (D7- and D8-) (figure 3.7A). Hox B1 and Hox B3 displayed this trend but at lower 
expression levels (data not presented). For Hox B9  a different pattern was observed as VPA 
delayed peak expression, expression peaked on day 5 in control samples (D5-) and on day 6 
for VPA treated samples (D6 WO) (figure 3.7B). Although there is fluctuation, as observed by 
the SEM. Overall, Hox B9 expression levels were lower than Hox B5. Pou5f1 expression was 
marginally increased in VPA samples on days 4, 5 and 6 but returned to control levels for 
days 7 and 8 (figure 3.2B).  
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Figure 3.7 The heritable effect of VPA on Hox B5 and Hox B9 
gene expression in differentiating ESC’s 
Log of Hox B5 and Hox B9 expression relative to GAPDH expression in 
undifferentiated (D0) and differentiating ESC’s (D2-D8). Addition of VPA (1mM) on 
D3 (D3+) for 8 hrs followed by VPA removal and incubation until day 8 (D8 WO). 
Samples harvested at 24 hour intervals. (A) Hox B5 expression (B) Hox B9 
expression. (n=3 -/+ SEM for three technical replicates) 
A 
B 
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3.8 TSA differentiation protocol 
To investigate whether VPA induced effects were unique an alternative HDACi was 
investigated, namely TSA. With the initial protocol being modified (figure 3.8). 
Undifferentiated ESCs were seeded on day 0 with LIF removal, RA addition followed on day 
2. 16 hours later (day 3) TSA addition to two groups and omission from one. After 8 hours 
TSA removed from one group but maintained within the other, producing three groups; no 
TSA, TSA wash out and continuous TSA. Samples harvested at 24 hour intervals until day 8.  
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Figure 3.8 TSA differentiation protocol 
Undifferentiated ESCs seeded on Day 0 with LIF removal.  RA addition on day 2. 
16 hours later (day 3) TSA added or omitted. Following 8 hours incubation TSA 
removed from one group of maintained. Samples harvested at 24 intervals until 
day 8.  
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3.9 HDACi TSA does not effect Hox B5 and Hox B9 expression nor does it 
display heritability  
To investigate the effect of TSA on Hox B5 gene expression the initial differentiation protocol 
was modified (figure 3.8). As a different HDACi was being investigated Hox B1-Hox B9 gene 
expression was determined. Expression of Hox B1-B9 was not detected in undifferentiated 
ESC’s (D0). Differentiated ESC’s displayed low Hox B expression, peaking at 1% for Hox B2 
expression, relative to GAPDH (data not shown). Overall a similar trend to the VPA induced 
effect (figure 3.5) was observed. TSA initially decreased gene expression on day 3, followed 
by increasing expression on days 4-6 and a return to control levels by day 8.  However, 
statistical analysis (-/+ SEM of three technical replicates) highlighted discrepancies within the 
data and as such no conclusive observation can be produced (data not shown). Pou5f1 
expression was higher in undifferentiated cells and declined in differentiating ESC’s, with TSA 
displaying no effect on expression (data not shown). 
3.10 Continuous TSA treatment may induce Hox B2 gene expression 
To further evaluate whether TSA effects Hox B gene expression in differentiating ESC’s TSA 
treatment was applied and maintained throughout differentiation (figure 3.8). With LIF 
removal on day 0, RA addition on day 2 and TSA (10ng/ml) added on day 3 and maintained 
until day 8 (D8C). Samples harvested at 24 intervals. With the exception of low Hox B2 gene 
expression, Hox B gene expression was not observed in undifferentiated ESC’s (D0). A trend 
was observed that by day 8 Hox B gene expression was increased in TSA positive samples 
(data not shown). However, due to variation between triplicate repeats, this observed trend 
may be negligible. Hox B2 gene expression displayed as an example (figure 3.9). Pou5f1 
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expression was not affected by TSA treatment and remained low throughout differentiation 





Figure 3.9 Effect of Continuous TSA treatment on Hox B2 gene 
expression in differentiating ESC’s 
Log of Hox B2 expression relative to GAPDH expression in undifferentiated 
(D0) and differentiating ESC’s (D3-D8). Addition of TSA (10ng/ml) on day 3 
and TSA maintained throughout differentiation (D3C-D8C). Samples 
harvested at 24 hour intervals. (n=3 -/+SEM of three technical replicates).  
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3.11 TSA decreases differentiating embryoid body size and number in vitro 
Although TSA has no effect on Hox B gene expression a visible difference in embryoid size 
and the number was observed during differentiation, when comparing control samples to 
TSA wash out and TSA samples. To confirm this observation light microscopy images (figure 
3.10A) were obtained and analysed using Image J (figure 3.10B)  An observed difference was 
displayed by day 5 (figure 3.10A), where embryoid body number and average size was 
greater in control samples than TSA wash out samples and TSA samples (figure 3.10). This 
trend was observed in day 6 and became more pronounced by day 7 and day 8. In addition, 
the morphology displayed by differentiating embryoid bodies was distinct from  
undifferentiated ESC’s (figure 3.10A). ESC’s were cultured as adherent to plastic ware, 
growing as a monolayer, whereas embryoid bodies were suspended within culture media as 
spherical colonies. To quantify this observation, images were analysed using image J. With 
the ‘2D’ area of 15 embryoid bodies per sample mapped and averaged to give the arbitrary 
values of figure 3.10B. The data confirms to some extent the difference observed between 
control samples and TSA wash out samples, particularly on day 6 (D6- against D6WO) and 
day 8 (D8- against D8WO). With an overall trend the average 2D area of embryoid bodies 
continuously cultured with TSA (D5C – D8C) is markedly reduced in comparison to control 
samples and TSA wash out samples. Furthermore, the average 2D embryoid body area size 
for control samples and TSA wash out samples decreased throughout differentiation, 
whereas embryoid bodies with continuous TSA maintained a lower average size (figure 
3.10B). 
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Differentiating ESC’s treated with TSA (10ng/ml) on day 3 for 8 hrs, following either
removal or maintained application(A) Morphological characteristics of undifferentiated
ESC’s (D0) in comparison to differentiating embryoid bodies (Day 5-8); TSA Wash Out,
Continuous TSA and control. Scale bar 0.2mm (B) Quantification of average embryoid
bodies area from day 5-8, without TSA (-), with TSA wash out (WO) and continuous TSA (C)
(n=15-/+SEM)
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4.1 HDACi’s do not affect Pou5f1 expression in differentiating ESC’s  
As expected Pou5f1 expression decreased throughout differentiation (figure 3.2) as Pou5f1 
is a known pluripotency gene predominately expressed in undifferentiated ESCs [54] [54-56], 
and the mouse embryo [26]. Pou5f1 expression  usually reduces as ESC’s differentiate [56] 
and previously declined in differentiating ESCs [57] (unpublished data). The effect of RA 
inducing differentiation was displayed as Pou5f1 gene expression levels were marginally 
higher in samples lacking RA (figure 3.2C). RA is published as inducing differentiation [58, 
59], particularly neurogenic differentiation [60, 61]. RA addition induced differentiation, 
indirectly reducing Pou5f1 expression. Further repetition would determine if the difference 
observed (figure 3.2C) due to RA is significant or not. Low Pou5f1 gene expression was 
maintained until day 8 (figure 3.2B), yet Pou5f1 expression in undifferentiated ESCs (D0) was 
reduced in comparison to previous experiments. This difference may be due to experimental 
error, in particular GAPDH expression variation. Further investigation would clarify this 
discrepancy. A similar effect of TSA on Pou5f1 expression in differentiating ESC’s was 
obtained. Pou5f1 expression was higher in undifferentiated ESCs and decreased throughout 
differentiation (data not shown). As no effect on Pou5f1 gene expression was induced by 
HDACi’s it could be hypothesised a protective mechanism prevents changes in gene 
expression levels. Although the fact Oct 4 contains retinoic acid response elements 
(RAREoct) targeted for RA-mediated repression may be the reason [62].  
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4.2 VPA increases Hox B1 gene expression  
HDACi VPA (1mM), when applied to differentiating ESC’s for 8 hours, increases Hox B1 
expression ~two fold in comparison to controls without VPA (figure 3.3B). A similar VPA 
induced Hox B1 expression increase has been previously observed in CCE/R ES cells [57] 
(unpublished data), although on undifferentiated ESCs. Although other evidence reports no 
VPA induced difference in Hox B1 expression (embryonic carcinoma cell line) [63] and this 
finding was not replicated in figure 3.4. Indeed, the effects of VPA on gene expression are 
varied with both increases [64] and decreases reported [65, 66]. In particular by recent 
microarray experimentation on HL60, a promyeloid leukaemia cell line, where both up 
regulated and down regulated VPA induced gene expression was observed, which varied 
over time [67]. Therefore further experimental repetition would be required to clarify or 
refute the validity of the finding, that VPA induces a  Hox B1 gene expression increase. It is 
possible the increase is natural fluctuation and a greater difference between the VPA 
positive (D3+) and VPA negative (D3-) samples would indicate a valid effect. This point is 
further highlighted by the lack of a VPA induced effect on the rest of the Hox B gene cluster 
(figure 3.2B).  
4.3 Effect of VPA on Hox B1 and Hox B9 is not heritable.  
To confirm or refute whether the initial VPA induced Hox B1 gene expression increase was 
heritable, samples were incubated for 24 hours following VPA removal. However, no 
heritable change was observed, in Hox B1 nor Hox B9 (figure 3.4). In addition, the VPA 
induced increase of Hox B1 expression (figure 3.3B) was not repeated. Further suggesting 
Hox B gene expression fluctuates greatly and the initial increase seen in figure 3.3 is due to 
such fluctuation. Separate experiments producing figure 3.4A displayed opposite results, 
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both an increase and decrease in Hox B1 gene expression on day 3 VPA samples (D3+) 
(individual data not shown). As for heritability no difference for Hox B1 expression was 
observed on day 4, thus no VPA induced heritability on Hox B1 gene expression is reported.  
Furthermore, no heritable Hox B9 gene expression change, induced by VPA, was observed 
(day 4, figure 3.4B). A difference in B9 expression was observed on day 3, where gene 
expression in control samples was higher than VPA positive samples. Although this result 
was not previously detected or repeated and the 3- value seems unusually high, indicating 
the Hox B9 D3- data is anomalous. Overall we report no VPA induced heritable effect on Hox 
B9 gene expression. However, there has been some evidence of Hox B1 and Hox B9 
heritability, as reported in mouse embryos treated with VPA in terms of histone 
modifications [26], but gene expression was not determined.  
4.4 VPA induces a heritable Hox B5 gene expression increase  
To further determine whether a VPA induced heritable change in Hox gene expression was 
possible the differentiation protocol was altered. After a longer differentiation period a 
heritable increase was observed for Hox B5 gene expression, 24 hours after VPA removal (D6 
WO, figure 3.6). As levels were above Pou5f1 expression in undifferentiated ESC’s the finding 
is deemed valid and not due to natural fluctuation. Further experimental replication would 
increase the validity of this claim. Supporting this heritable increase is Hox B9 expression 
which increased post VPA removal (figure 3.6B), although at lower levels.  
A heritable VPA induced epigenetic change has been previously reported in a different 
model, studying histone modifications rather than gene expression [26]. An increase in 
H4K8ac (acetylation) and H3K4me3 (trimethylation) of both Hox B1 and Hox B9 was 
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observed in mouse blastocysts, following VPA removal and 24 hour incubation [26]. To an 
extent this supports the proof of concept that HDACi induced changes can be heritable. 
Furthermore, recent unpublished data displayed a similar increase in Hox B5 gene 
expression in differentiating ESCs [57]. The effect was post VPA removal and therefore 
heritable, however the differentiation protocol varied in terms of VPA addition, LIF removal, 
RA addition [57].   
For Hox B1 no effect was observed (data not shown) due to low expression levels, suggesting 
in this instance Hox B1 expression was negligible. As Hox B1 expression was greater in the 
previous differentiation protocol it suggests VPA induced effects are dependent upon the 
differentiation protocol. As such applying VPA treatment at an appropriate time, in regards 
to natural Hox B gene expression, may display different results. This line of thought is 
supported by the observation of sequential Hox B gene cluster expression seen in ESC 
differentiation [57]. Hox B1 gene expression may have diminished by the time VPA was 
added on day 5. Perhaps earlier application of VPA would induce a heritable change in Hox 
B1 expression, such as in combination with RA on day 2. Particularly as Hox B1 is a key target 
gene of RA and contains a RARE [36]. A knockout of the polycomb protein complex, may 
elucidate the conflicting findings, as polycomb proteins suppress Hox genes [28].    
4.5 VPA induces a heritable Hox B5 gene expression increase for 72 hours 
To confirm the heritable effect of VPA induced Hox B5 gene expression increase and 
whether this increase was maintained, sample incubation was extended. A heritable 
increase in Hox B5 gene expression due to VPA was observed for 72 hours, with a decrease 
following (figure 3.7A). By day 7 and day 8 samples treated with VPA (D7WO and D8WO, 
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respectively) were lower than control levels (D7- and D8-). Such a trend implies the initial 
VPA induced effect has been counteracted, perhaps by a protective mechanism preventing 
increases in gene expression. Such a concept is proposed as recent work studying the effect 
of VPA on histone modifications showed genes being sheltered from the effects of HDACi’s, 
including VPA [67]. Furthermore, overall expression levels of Hox B5 were reduced during 
this differentiation protocol, than previously reported (figure 3.6). This may be due to 
variation of the differentiation protocol. For figure 3.7 samples were differentiated for 
reduced time period than figure 3.6. Again highlighting the possibility for an induced 
inheritable change to occur, VPA has to be applied at the correct time in relation to natural 
Hox B gene expression. Each gene having a period of normal expression, where VPA has the 
potential to cause the greatest effect.  
A similar pattern to Hox B5 gene expression was observed for Hox B1 and Hox B3 but at 
lower expression levels (data not shown) and differences between VPA treatment and 
control samples could be negligible.  
Hox B9 gene expression displayed a different pattern (figure 3.7B), with an implied delay in 
peak expression induced by VPA (D6WO compared to D5-). However such an assumption 
would require further investigation to validate or refute the claim.     
4.6 HDACi TSA does not effect Hox B5 and Hox B9 gene expression nor does 
it display heritability 
 An alternative HDACi, TSA, was investigated to confirm or refute the previous findings, that 
VPA induces a Hox B5 gene expression increase.  Under the application of TSA Hox B5 gene 
expression displayed a similar trend to VPA (figure 3.7). An initial decrease in VPA samples 
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on day 3 followed by an increase over control levels, before a final decrease. However, 
expression levels for TSA samples were lower in comparison to  VPA and there was a great 
deal of variation within qRT-PCR data, as displayed by the SEM (data not shown). As such the 
data does not imply any effect due to TSA or any heritability. Although the rest of the Hox B 
gene cluster data displayed a similar pattern, albeit at lower levels. With further 
investigation the SEM may be reduced, and a trend could become apparent, with TSA 
effecting Hox B gene expression. One factor involved could be normalising data against 
GAPDH, as GAPDH expression is much greater than Hox B gene expression. The use of an 
alternative housekeeping gene which is stable but expressed at lower levels (i.e. TBP) may 
solve the problem [68] by increasing relative Hox B gene expression in comparison to the 
housekeeping gene. Pou5f1 expression in differentiating ESC’s displayed lower expression 
levels than undifferentiated ESCs (data not shown). Interestingly Pou5f1 expression was 
increased by TSA on day 3, day 4 and day 5. Implying a heritable TSA effect , that TSA delays 
the reduction of Pou5f1 gene expression in differentiating ESC’s. However, due to the 
aforementioned questionability of the TSA data, further investigation would be desirable 
before drawing such conclusions confidently.   
4.7 Continuous TSA treatment may induce Hox B2 gene expression increase 
Further investigation into the effect of TSA on Hox B gene expression in differentiating ESC’s 
displayed an increase in Hox gene expression by day 8, when TSA application was 
maintained. This effect was more pronounced in Hox B2 (figure 3.9). However, variation 
within the qRT-PCR data was apparent producing large SEM values. Although the majority of 
the Hox B genes displayed the same trend implying, with experimental repetition to increase 
the ‘n’ number and reduce the SEM, the trend may be valid. However no conclusive 
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observations can currently be drawn.  Alternatively using of a housekeeping gene with lower 
expression levels [68], may aid SEM reduction. Of all the Hox B genes, Hox B7 displayed the 
lowest expression levels (data not displayed), but the highest value for Hox B7 obtained was 
in day 8 of continuous TSA application. Implying TSA may have switched on gene expression, 
but such conclusions should be taken lightly due to low expression levels, relatively large 
SEM and the requirement for further work.  
If the trend of increased Hox gene expression by day 8 was proven valid it opens up the 
question of why a difference in gene expression was not observed until day 8. One 
suggestion being a protective mechanism preventing and sheltering genes from the effects 
of HDACi’s [67]. With an effect not being displayed until such a mechanism is overcome.  
Further work to be undertaken would include extending the culture period beyond day 8 to 
investigate whether the possible TSA induced increase is lost, stays constant or increases 
further.  
4.8 TSA decreases differentiating embryoid body size and number, in vitro 
During the culture period TSA reduced the number and overall size of differentiating ESC 
embryoid bodies (figure 3.10). This reduction was pronounced within continuous TSA 
samples. Morphological effects induced by TSA have been previously reported with TSA 
disrupting colony formation, although in undifferentiated ESCs [69]. A possibility for the 
reduced proliferation is TSA stimulating differentiation [70]. The effect of TSA on reducing 
the size of differentiating embryoid bodies was quantified via the use of Image J and 
mapping the 2D area (figure 3.10B), with results displaying a trend supporting the initial 
observation. However, statistical analysis (SEM) on the average embryoid area was not as 
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conclusive. This is likely due to the nature of embryoid bodies, which vary in size, from those 
initially formed and hours old, to those more developed and days old. Although statistically 
the evidence does not support a significant effect, a visible trend is still observed. 
Furthermore, repetition with an emphasis on producing more imaging for analysis could 
provide evidence to quantify the observed trend. Alternatively, grouping the size of 
embryoid bodies measured to determine if the size group percentage as a whole changes 
due to TSA treatment, i.e. no TSA treatment is likely to produce a larger percentage of 
embrypid bodies in a ‘large size category’ in comparison to continuous TSA treatment, which 
is likely to produce a lower percentage of ‘large embryoid bodies’ and a higher percentage of 
‘small embryoid bodies’. In addition, the same principle could be applied to VPA cultured 
embryoid bodies to determine whether a similar effect is occurring.  
For TSA negative data a decrease in size was observed during differentiation (compare D6- 
to D8-), though this is likely due to culture methodology. Embryoid bodies are suspended 
within culture media and when media is replenished a number of embryoid bodies will have 
been inadvertently lost. As all sample were treated the same, a similar level of loss due to 
will have occurred in both TSA wash out and continuous TSA samples. As such the observed 
trend is deemed valid and not due to an experimental artefact.  
4.9 Implications  
The heritable VPA induced change in Hox B5 gene expression (figure 3.6) provides a proof of 
concept that HDACi’s can effect gene expression which is heritable through mitosis. As VPA 
is a fatty acid and represents an environmental agent [2] it opens the idea other agents or 
drugs could have a similar effect. If the VPA effect is proven it questions the safety of the 
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drug within pregnancy. VPA is teratogenic in fish embryogenesis [71], could a similar effect 
be seen in human ESCs and to what extent is a human foetus vulnerable, does the placental 
barrier provide enough protection, especially as VPA is associated with autism spectrum 
disorders [72] and neurulation defects [73]. Indeed the use of VPA in pregnant women is not 
recommended and patients should use other anti-epileptic drugs with lower teratogenic 
risks where possible or reduce VPA treatment to the lowest effective level [74], as 1000+ mg 
per day causes the greatest increase in teratogenic risk to the foetus [74] but effects have 
been seen at 600 mg a day [75].  TSA is also documented to be teratogenic [76] and could 
have similar human foetal implications.   
4.10 Further work 
Apart from aforementioned repetition, further investigation is required into the heritable 
effect of HDACi’s. As previously reported [26] a heritable effect in histone modifications is 
observed within mouse embryos, so it could be determined whether similar findings are 
observed in an ESC line though the use of CHIP (chromatin immunoprecipitation) [77]. Also, 
whether Hox B gene expression differences coincide with histone modification changes. 
Modifying the differentiation protocol may allow the discovery of heritable changes induced 
by HDACi on other Hox genes. Although it is reported in a few cases that a heritable effect 
on HoX B gene expression was observerd due to VPA treatment it may be possible that the 
gene expression changes are due to sub- population within the cell culture, this 
subpopulation could still be displaying gene expression changes due to VPA and may not 
have undergone mitosis, whereas the remaining population have undergone mitosis and do 
not display gene expression changes. If this were the case the VPA induced gene expression 
changes would not be heritable and this problem would need to be overcome to confirm 
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gene expression changes are produced by daughter cells and not an un-proliferative 
subpopulation within the cell culture.  In addition, investigating the effect of other HDACi to 
determine whether the findings reported are specific to VPA or not. In addition, FACs 
analysis could be useful in confirming the effect of HDACi on the cell cycle, i.e. in figure 9, 
does TSA reduce proliferation by altering the cell cycle. Lastly further experimental 
repetition would allow statistical analysis to be undertaken and allow greater confidence in 
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4.11 Concluding Remarks 
To test the hypothesis that epigenetic effects are heritable through mitosis, a differentiating 
mouse ESC model using HDACi’s VPA and TSA on Hox B gene expression was utilised. To 
confirm differentiation Pou5f1 expression was analysed, with a reduction in expression 
observed throughout differentiation. Preliminary studies on the effect of VPA on Hox B 
genes displayed a VPA induced increase in Hox B1 gene expression. However, further 
investigation did not replicate this finding, leading to the conclusion VPA does not cause a 
Hox B1 gene expression increase, with no heritability observed. Expression of other Hox B 
genes was low and negligible. On modification of the differentiation protocol it was 
observed VPA induced a heritable increase in Hox B5 gene expression and to a lesser extent 
Hox B9. Hox B3 and Hox B1 showed no VPA induced effect. The VPA induced increase in Hox 
B5 gene expression was maintained for 72 hours post VPA removal, before expression levels 
fell to control values. TSA was investigated to determine if the observed effects were unique 
to VPA induction. TSA however, did not conclusively show Hox B gene expression increases, 
or decreases. Yet continuous TSA application may induce Hox B2 gene expression but further 
investigation is required to confirm or refute this finding. However, TSA did reduce the 
number and average area of embrypid bodies. Overall, through Hox B5 gene expression, a 
proof of concept for epigenetic heritable changes is reported. Although further work is 
required to confirm this conclusion
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Mesenchymal Stem cells (MSCs) are an adult population of self-renewing pluripotent stem 
cells.  MSCs are defined through plastic adherence, cell surface marker expression and their 
multi-lineage differentiation potential; adipogenic, osteogenic and chondrogenic. First 
isolated from bone marrow, MSCs are also found within dental tissue. Namely; dental pulp 
stem cells (DPSCs), stem cells from human exfoliated deciduous teeth (SHED), stem cells 
from the apical papilla (SCAP), periodontal ligament stem cells (PDLSC) and dental follicle 
precursor cells (DFPC). MSCs also spontaneously express early neuronal markers, leading to 
the hypothesis MSCs have neurogenic differentiation potential. As such In vitro manipulation 
of MSCs via chemical and cytokine induction has investigated their neurogenic potential.  
Supporting MSCs neurogenic potential are morphological changes, up-regulation of neural 
marker expression and functional neuronal analysis. With the hypothesis that dental derived 
MSCs may provide a more useful source of MSCs than bone marrow for neurogenic 
differentiation, due to dental derived MSCs increased proliferation rates, accessibility and 
neural-crest origin. Furthermore, MSCs may be beneficial for a range of neurological 
diseases, such as; Parkinson’s Disease, Huntington’s Disease, Amyotrophic Lateral Sclerosis 
and spinal cord injury. Although promising, further investigation is still required. 
  







Mesenchymal stem cells (MSCs) are an adult source of stem cells prized for their potential 
within tissue engineering, repair and regeneration. MSCs were first isolated from bone 
marrow [11] but over the last decade they have been found in dental tissue, including dental 
pulp of adult teeth [12, 13] and dental pulp of exfoliated deciduous teeth [15]. MSCs are 
defined as being able to differentiate into adipogenic, osteogenic and chondrogenic lineages, 
[2] along with surface marker expression characteristics [16]. However, they display early 
neuronal markers [17] and it’s hypothesised they have neurogenic potential, which is 
confirmed via induced in vitro neurogenic differentiation. MSCs from dental sources have 
generated interest due to their availability and neuro-crest origin [18-20]. With the 
hypothesis DPSCs may provide a better autologous source of MSCs for neurogenic 
differentiation and use within treating neurological conditions [21, 22].  This review aims to 
investigate that claim. First with the classification and characterisation of MSCs from bone 
marrow and dental tissue. Followed by highlighting in vitro conditions required for 
neurogenic differentiation, with an emphasis on dental tissue studies. Finally summarising 












1.2 Classification of Stem Cells  
Stem cells (SC) have the ability to self-renew and differentiate into specialised cells, via the 
formation of intermediate precursor cells (see figure 1.1) [4]. The self-renewing capability 
allows SCs to expand by mitosis, hence maintaining the population [23]. SCs have the ability 
to differentiate into different cell types, termed potency which is further subdivided, 
depending upon differentiation potential. Post fertilisation and until the morula stage the 
embryo is totipotent; the cells can potentially differentiate into any cell of the foetus and 
placenta [24]. Once a blastocyst is formed (figure 1.1), the inner cell mass develops into the 
foetus and not the placenta, termed pluripotent, their differentiation capacity reduced 
compared to totipotent cells [25]. As SCs differentiate they become less potent [26], with 
the next level termed multipotent, these are adult SCs and differentiate into cells from 
restricted cell lineages (figure 1.1), related usually to location/microenvironment. Adult SCs 
are located in a wide range of tissues, for example; bone marrow [2], dental tissue [12, 15], 
spleen [27], umbilical cord [28], placenta [29]  and adipose [30-32]. MSCs are one group of 
adult SCs that have stimulated interest due to their relatively easy isolation and self-
renewing capacity, allowing in vitro expansion. These properties appeal to scientists and 
clinicians due MSCS potential within tissue engineering, repair and regeneration. 







1.3 Characterisation of Mesenchymal Stem Cells 
MSCs were isolated by Friedenstein et al [11] from bone marrow and formed fibroblast-like 
cells, differing morphologically from haematopoietic cell types. MSCs displayed plastic 
adherence, allowing separation from haematopoietic cells [33]. Although most commonly 
referred to as ‘Mesenchymal Stem Cells’ MSCs were labelled as bone marrow fibroblasts, 
bone marrow stromal cells, multipotent adult progenitor cells and skeletal stem cells [34], 
due to a lack of definition. Multiple factors were utilised in defining MSCs; plastic adherence, 
Figure 1.1 Stem Cell Potency 
Schematic representing stem cell potency. Embryonic stem cells prior to 
blastocyst formation are totipotent. ICM of blastocyst are pluripotent and 
have capacity to self-renew and differentiate into the germ layers; 
endoderm, mesoderm and ectoderm. Upon differentiation germ layer 
derived stem cells are multipotent, such as mesenchymal stem cells, neural 
stem cells and haematopoietic stem cells. [4] 






morphology, differentiation derivatives and cell surface marker expression. However, a clear 
definition was published in 2006, by the Mesenchymal and Tissue Stem Cell Committee of 
the International Society for Cellular Therapy [16]. With the parameters being plastic 
adherence, in vitro differentiation into osteogenic, adipogenic and chondrogenic cell lines 
(see figure 2.1) and specific cell surface marker expression.  In particular, over 95% of a 
cultured MSC population are positive for CD105, CD73 and CD90 whereas less than 2% are 
positive for CD45, CD34, CD14, CD11, CD79, CD19 and HLA class I [16]. A definition of these 
markers is provided in table 1.1, along with other commonly used markers. The purpose of 
both positive and negative expression to confirm isolated cells are not of haematopoietic 
lineage. Furthermore, MSCs are unable to differentiate into haematopoietic cell types [35].  
 
Table 1.1: List of mesenchymal stem cell markers, the percentage expression and their 
definition. 2006 Mesenchymal and Tissue Stem Cell Committee markers, including other 
regularly used markers and theirr positive or negative expression requirement to confirm a 
cell population as MSCs [5, 16, 22, 36] 
 
Marker Percentage (%) Definition 
2006 Mesenchymal and Tissue Stem Cell Committee Definition 
CD73 95 Plasma Membrane Protein 
CD90 95 Extracellular matrix protein – 
Thy-1 T cell surface 
glycoprotein 
CD105 95 Adhesion molecule – SH-2, 







CD11 <2 Monocyte/Macrophage 
CD14 <2 Monocyte/Macrophage 
CD19 <2 B cell marker 
CD34 <2 Haematopoietic progenitor 
and endothelial marker 
CD45 <2 Pan-leucocyte common 
antigen 
CD79 <2 B cell marker 
HLA Class II <2 Part of the Major 
Histocompatibility Complex 
 
Other Markers Used 
Marker Expression Definition 
STRO-1 Positive  Putative MSC marker 
CD9 Positive Adhesion molecule -  
tetraspannin receptor 
CD10 Positive Surface enzyme – common 
leucocyte lymphocytic 
leukaemia antigen 
CD13 Positive Surface enzyme – 
aminopeptidase N 
CD29 Positive Adhesion molecule – Integrin 







CD44 Positive Lymphocyte homing-
associated cell adhesion 
molecule 
CD49d Positive Adhesion molecule – integrin 
α2 
CD59 Positive Complement regulatory 
protein – protectin 
CD106 Positive Adhesion molecule – 
vascular cells 
CD146 Positive Adhesion molecule – 
Endothelial cell lineage 
CD166 Positive MSC marker- activated 
leucocyte cell adhesion 
molecule 
CD31 Negative Endothelial cell marker – 
platelet endothelial cell 
adhesion molecule 
CD117 Negative Haematopoietic stem cell 
marker 
 
MSCs morphology is fusiform and spindle-like in shape, similar to fibroblasts, with a 
relatively small cell body and a couple of outward projecting processes (see figure 1.2A) [2]. 
In vitro, MSCs initially form a spherical morphology prior to a monolayer fibroblast-like 






morphology [37].  MSCs differentiate into osteogenic, adipogenic and chondrogenic cell 
types [2]  (figure 1.2), hence inclusion of this criteria within the 2006 requirements [16].  
 
1.4 MSC Sources and Characteristics 
 1.4.1 Bone Marrow 
MSCs can obtained from many adult tissues but the first and most common isolation source 
is bone marrow [37]. Bone marrow contains two stem cell populations; haematopoietic stem 
cells (HSC) and MSCs (although MSCs number is low at 0.01% of total bone marrow 
















(A) Undifferentiated bone marrow derived mesenchymal stem cells, 
displaying a fibroblast-like spindle shaped morphology. (B) Adipogenic 
differentiation with oil red O positive staining for neutral lipid vacuoles (C) 
Chondrogenic differentiation with antibody staining for  type II collagen (D) 
Osteogenic differentiation with staining for alkaline phosphatase. Modified 
from Pittenger et al [2]. 






population) [2], hence the need to confirm non haematopoietic contamination via cell 
surface marker expression. The first protocols for isolation and culture of homogeneous 
bone marrow derived MSCs (BM-MSCs) were established  in the 90’s [38] and involved 
aspiration of bone marrow which  then cultured on plastic and non-adherent 
haematopoietic cells within the media are removed [36].  The pelvic superior iliac crest is the 
primary source for BM-MSCs, although other sources include tibial and femoral 
compartments and thoracic and lumbar spine [39].  BM-MSCs display classic fibroblast 
spindle-shaped morphology [36, 40, 41] (see figure 1.2A)  and MSC marker expression (see 
table 1.1), including high levels for CD73 and CD90 and low levels for CD11, CD14, CD19, 
CD34 and CD45 [36].  Extended BM-MSC culture is possible, up to 30 passages [40]. BM-
MSCs multi-lineage potential is confirmed as osteogenic, adipogenic and chondrogenic, [2, 
36, 40, 41]) (figure 1.2).   
 1.4.2 Dental Pulp Stem Cells  
MSC like cells have been isolated from numerous dental tissues. The first being postnatal 
human dental pulp stem cells (DPSCs), isolated in 2000 [12]. Until then the precursor cell 
population giving rise to odontoblasts was poorly understood and the group hypothesised 
dental pulp (DP) tissue may contain a MSC population (figure 2.1) [12]. Human impacted 
third molars were obtained, due to their ease of access and normal disposure as clinical 
waste, and treated with enzymatic solutions (3mg/ml collagenase and 4mg/ml dispase) to 
dissociate DP cells [12]. Isolated DPSCs and BM-MSCs were studied in terms of 
immunohistochemistry and gene expression [13]. In direct comparison to BM-MSCs, DPSCs 
showed fibroblast-like morphology, a higher colony forming cell frequency and an increased 
number of proliferating cells (72% for DPSCs against 46% for BM-MSCs) [13].  






Immunohistochemical analysis of cell surface marker expression revealed DPSCs and BM-
MSCs displayed similar characteristics. However, marker expression was not unanimous and 
as thus DPSCs are a heterogeneous population [12, 13]. Overall, isolated DPSCs have similar 
properties to BM-MSCs.  
DPSCs were later isolated and characterised by FACs analysis [13] (see figure 1.4), in 
particular their capacity for self-renewal, proliferation and differentiation potential. Human 
DPSCs, when implanted into a mouse, displayed an in vivo capacity for self-renewal [13]. As 
for proliferation, 20% of DPSCs were cultured above 20 population doublings, with the 
remaining 80% between 10 and 20 population doublings. [42]. Therefore, DPSCs population 
contains subpopulations with varying degrees of proliferative potential [13]. DPSCs  have the 
potential to form adipose and neuronal tissue, confirmed by positive expression of oil red O-
positive lipid clusters and nestin, plus glial fibrillary acid protein (GFAP), respectively [13].  
Since isolation via enzymatic digestion [12] an alternative method involves cellular 
outgrowth from pulp tissue extracts [43]. This method generates different cell populations 
compared to those obtained using enzymatic digestion, and suffers from a lower 
proliferation rate [43], possibly due to the heterogeneous nature of DP. Thus most studies 
use enzymatic digestion to isolate DPSCs (see table 2.2).  
DPSCs populate the central tooth cavity (figure 1.2), which contains pulp tissue, [44] also 
known as the perivascular niche and DPSCs originate from migrating neural crest cells [18, 
45]. The neural crest forms in development between the neural plate and non-neural 
ectoderm [1]. Neural crest cells (NCC) are multipotent with a wide differentiation potential 
[1] and cranial NCCs can produce MSCs [1]. Furthermore, DPSC differentiation capacity has  
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expanded to odontoblastic, osteoblastic, osteocytes, chondrocytes and adipocytes [19, 44, 
46-48]. Although primarily isolated from 3rd molars, DPSCs have been isolated and 
characterized from supernumerary teeth [48], displaying spindle shaped morphology (see 
figure 1.4) and adipogenic and osteogenic differentiation potential [48]. DPSCs can also be 
isolated from an earlier stage of tooth development [49] , the crown-completed stage, 
rather than the later root-completed stage [49]. Morphologically DPSCs display the 
fibroblast-like spindle shape associated with other MSCs [1]. On a final and interesting note 
DPSCs have been successfully isolated from teeth 5 days after initial tooth extraction, 
recovered after the cryopreservation of whole teeth and are able to maintain their multi-
lineage differentiation potential post cryopreservation [50]. Thus highlighting the potential 
DPSCs have for future tissue banking [9].  
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1.4.3 Stem cells from Human Exfoliated Deciduous teeth 
As MSC have been obtained from adult teeth it is feasible to propose a population exists in 
deciduous (milk) teeth. Indeed a population of stem cells are present in human exfoliated 
deciduous teeth, known as SHED (stem cells from human exfoliated deciduous teeth) [15]. 
Enzymatic digestion of 7-8 year old incisors provided the DP, containing SHEDs [15] (see 
figure 1.3).  Akin to DPSCs, SHEDs display higher proliferation rates than BM-MSCs and 
higher population doublings [15] (see figure 1.4). Interestingly both properties were higher 
in SHEDs than DPSCs [15]. As for cell marker expression, SHED  were positive for MSC 
markers Stro-1 and CD146, markers confirmed in DPSC and BM-MSC populations [15]. For 
Figure 1.3 Diagram of a human adult tooth 
(A) Cross-section of a tooth displaying cells and structures of a tooth. The dental pulp (purple) 
is in the centre, source of dental pulp stem cells (DPSC) in adults and stem cells from human 
exfoliated deciduous teeth (SHED) in milk teeth. The periodontal ligament (pink) providing 
periodontal ligament stem cells (PDLSC) and the apical papilla (lilac)  giving rise to stem cells 
from the apical papilla (SCAP). (B) Photograph of tooth indicating locations of aforementioned 
structures. Taken from Volponi et al. 
A B 
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differentiation capability SHEDs formed odontoblasts and oil red O-positive adipocytes. 
Overall, SHEDs exhibited a multipotent stem cell population source, similar to DPSCs but 
displaying different properties due to their immature nature [15].  Indeed a difference in 
gene expression profiles was observed, with 4,386 genes displaying a difference of at least 
2.0 fold [5]. The increased proliferation rate of SHEDs over both DPSCs and BM-MSCS’s has 
been confirmed, [5]. Stro-1 expression was confirmed in all 3 populations by the same group 
and typical MSC fibroblast-like morphology [5]. Overall, SHEDs may provide a useful source 
of MSCs for future use within tissue engineering and regenerative medicine, as they are 
capable of differentiating into osteoblasts, odontoblasts, adipocytes, chondrocytes, 
myocytes and neuronal tissue [5, 47]. In addition, banking SHEDs via cryopreservation could 
be beneficial for later life in terms of stem cell therapy and cell replacement [51]. 
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Figure 1.4 Characteristics of Dental derived mesenchymal stem cells 
Microscopy imaging displaying the fibroblast like spindle morphology of (A) 
DPSCs (Dental pulp stem cells) Taken from Varga et al [1]. Scale bar = 20 μm (B) 
SHED (stem cells from human exfoliated teeth) Taken from Nakamura et al ([5] 
(X40) and  (C) SCAP  (stem cells from the apical papilla) Taken from Ding et al [7]. 
Scale bar = 2.0 mm (D) Flow cytometry of DPSCs with positive expression of MSC 
markers CD105, CD73 and CD90 Taken from Perry et al [9] (E) and (F) 
Proliferation rates of BM-MSCs, DPSCs and SHEDs. Taken from Nakamura et al [5] 
-LIF respectively. - LIF 
F 
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1.4.4 Stem Cells from Apical Papilla 
Another dental source of MSCs is derived from the apical papilla, an area attached to the 
developing tooth root (figure 2.1), and abbreviated as SCAP (stem cells from apical papilla). 
This region being the precursor tissue for radicular pulp [47]. SCAP cells were isolated from 
extracted third molars and enzymatically digested [52]. When cultured, SCAPs formed 
adherent clusters and could differentiate into osteogenic and adipogenic lineages [52]. 
Further investigation highlights a high proliferation rate, neurogenic marker expression and 
their distinction from DPSCs [53].  
Furthermore, the isolation of SCAP from cryopreserved teeth has been proven [7]. When 
compared against freshly isolated SCAP, cryopreserved SCAP (cSCAP) maintained fibroblast-
like morphology (see figure 1.4) and no significant decrease in cellular viability, colony 
formation or cell proliferation was observed. In addition, Stro-1 and CD146 expression was 
confirmed and cSCAP could differentiate into adipocytes and odontogenic cells [7]. Such 
characteristics suggest potential for tissue banking of SCAP for future use.  
1.4.5 Periodontal Ligament Stem Cells 
Dental tissue derived stem cells can be located within the periodontal ligament (PDL), a 
fibrous and vascularised connective tissue supporting the tooth [54] (figure 1.3), with the 
population termed periodontal ligament stem cells (PDLSC). Impacted human 3rd molars are 
the primary source and cultured periodontal ligament cells are scraped from the middle 
third of the root before enzymatic digestion [54, 55]. FACS analysis determined the 
population as positive for MSC markers, namely Stro-1, CD105 and CD166 and negative 
(<2%) for CD34, CD45, CD117 and CD31. [54, 55]. Although Stro-1 staining varies (generally 
low), possibly due to the heterogeneous nature of the isolated population. As for SC 
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properties, PDLSCs display higher proliferation rates, nearly double at 96 hours, and an 
increased number of SC colony forming units, compared to BM-MSCs [54]. Furthermore, 
multi-differentiation potential has been confirmed as tissue of mesenchyme origin: 
adipogenic, osteogenic and chondrogenic [54]. Thus, the PDL provides a source of SCs which 
may be useful in future regenerative medicine.  
1.4.6 Dental Follicle Precursor Cells 
Related to PDLSCs are a group known as dental follicle precursor cells (DFPC). The dental 
follicle (DF) being connective tissue surrounding the developing tooth [56]. DFPCs are linked 
to PDLSCs as the DF contains  precursor cells to the peridontium, which in turn includes the 
PDL, cememtum and alveolar bone [57]. Extracted 3rd molars are utilised and the DF isolated 
from the tooth before enzymatic digestion [56]. Plastic adherence isolates the small cell 
number that produces DFPCs, which display fibroblast-like morphology. Amongst the 
markers investigated DFPCs were positive for Notch-1, a neural stem cell marker and Nestin, 
which is present in tooth development and was proposed to be a marker for 
neuroectodermal and mesenchymal linerages [56]. DFPCs are positive for Stro-1, CD9, CD29, 
CD49d, CD105, CD106, CD166, CD44, CD10, CD13, CD90 and CD59 and negative for CD31 
and CD45 [44]. As for differentiation potential rat DFPCs form osteogenic and adipogenic 
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2.1 MSCs: Potential for Neural Differentiation 
Along with the differentiation potential of chondrogenic, adipogenic and osteogenic cell 
lines, MSCs can differentiate into other cell types, such as the neuronal route. This 
neurogenic potential is highlighted through the discovery of dental tissue MSCs. As in early 
studies neurogenic differentiation was often utilised in characterising the isolated cell 
populations [13, 15], even before their chondrogenic, adipogenic and osteogenic potential. 
This occured when DPSCs were first isolated as they expressed both nestin, a neural 
precursor, and GFAP, a glial cell precursor [13]. In a similar fashion SHEDs were studied for 
neural potential following their first isolation [15]. With positive expression for neural 
markers; nestin, βIII-tubulin, neuron-specific nuclear protein (NeuN), GFAP, neurofilament 
medium (NF-M) and 2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNPase) (see table 2.1).  
Furthermore, culturing in conditions inductive to neuronal differentiation a number of 
neuronal markers increased expression; BIII-tubulin, Glutamate decarboxylase (GAD) and 
NeuN. [15].  
However not just dental derived MSCs display this phenomenon, with BM-MSCs reported to 
spontaneously express neural markers [17]. These tend to be early markers such as nestin 
and βIII-tubulin, having been observed in 80% of MSCs [59]. With weaker expression (<20%) 
of mature neuron and glia markers, namely; microtubule-associated protein 2 (Map-2), 
tyrosine hydroxylase (TH) and GFAP, which do not increase until MSC neuronal induction 
[59]. Others report high nestin expression (near 100%), and other neural markers at lower 
levels; β-III tubulin (12%) and N--FM (13.2%) [17]. In addition, expression of nestin, TH and 
Nurr1 has been presented, along with rat BM-MSCs displaying neurosphere-like structures 
as evidence for MSC neurogenic potential [60].  
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Therefore, the initial belief that adult SCs were limited in differentiation potential to specific 
lineages has been overcome. The ability that some SCs can differentiate into cells from 
different lineages, those not associated with their origin, has been termed trans-
differentiation [33, 39].  For trans-differentiation to occur SCs are believed to undergo 
genetic reprogramming and it is suggested ‘master genes’ control this process. With either 
gene suppression or activation triggering cellular differentiation [39]. However, it is worth 
noting that the original use of the term trans-differentiation was for the ability of a fully 
differentiated cell to become a different differentiated cell and the term trans-
differentiation should be used with caution [39].  
Recently the field of neurogenic differentiation of MSCs has expanded with numerous 
protocols and cell markers used to define various neuronal cell types which have been 
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Table 2.1: List of commonly used neuronal markers, along with their abbreviation and 
description. [10, 13-15, 17, 41, 59-63]  
Marker Abbreviation  Description/meaning 
Nestin - Neural associated 
Intermediate filament  
Vimentin - Mesenchymal associated 
intermediate filament 
Notch -1 - Transmembrane Receptor 
Neurotrophic tyrosine 
kinase receptor type 1 
TrkA Nerve growth factor 
receptor 
Tau - Microtubule associated 
protein (Alzheimers)  
Neuron-specific enolase or 
enolase 2 
NSE or Eno2 metabolism enzyme found in 
mature neurons 




NeuN Neuronal nuclear antigen 
Neurofilament Light NF-L Neuron specific intermediate 
filament 
Neurofilament Medium NF-M Neuron specific intermediate 
filament 
Neurofilament Heavy NF-H Neuron specific Intermediate 
filament 
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MAP2 Stabilizes microtubules in 
neurogenesis 
Neurotrophic tyrosine 
kinase receptor type 2 
TrKB Neurotrophin receptor 
Neural cell adhesion 
molecule 
NCAM/ CD56 Surface glycoprotein 
 Gal-C  
Class III β-tubulin βIII-tubulin (Tuj1) Neuron associated 
microtubule 





c-fos - Indirect protein marker of 
neural activity 




BMP2 Promotes Neurogenesis 
SRY (Sex determining region 
Y ) -box 2 
Sox2 Transcription factor 
SRY (Sex determining region 
Y ) -box 9 
Sox9 Transcription factor 
Neuromodulin/Growth 
Associated Protein 43 
NMD / GAP-43 Neural specific protein 
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Galanin GAL Neuropeptide 
Tachykinin TAC1 Neuropeptide 
Cluster of Differentiation 81 
/ Target of the 
antiproliferative antibody 1 
CD81 / TAPA 1 Surface protein of neural 
progenitor cells – Also B cells 
S-100 Protein S100 Neural crest associated 
protein 
Nuclear receptor related 1 
protein 
Nurr1 Inscription factor inducing 
TH 
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2.2 In Vitro conditions for Neurogenic Differentiation 
2.2.1 Bone Marrow 
To induce neuronal differentiation numerous protocols have been explored, ranging from 
cytokine growth factors to chemical inducers. Amongst the cytokines, basic fibroblast growth 
factor (bFGF) is the most prevalent, with 25ng/ml  inducing neural differentiation of BM-
MSCs [64]. Under bFGF influence mouse MSCs developed neural-like morphology with 
dendrite-like projections, when cultured on poly(lysine)-coated dishes [64]. Nestin was 
detected in undifferentiated MSCs and increased due to bFGF, with a more developed 
filamentous network observed [64]. In addition an increase in neurofilament-light (NF-L) and 
βIII-tubulin expression but GFAP was not detected [64].  The effect of bFGF is supported, 
often alongside epidermal growth factor (EGF). With both factors generating neuronal-like 
morphological cells [61] and expression of nestin, NeuN, and GFAP [65]. With others 
culturing EGF and bFGF before later addition of Retinoic acid (RA) and β-nerve growth factor 
(β-NGF) [41]. With nestin, β III-tubulin and neurofilament-medium (NF-M) expression by day 
12 of differentiation [41]. Further support is more extensive and utilises other growth 
factors, in particular 10ng/ml EGF, 20ng/ml hepatocyte growth factor (HGF) and 20ng/ml 
vascular endothelial growth factor (VEGF), but not bFGF [62]. Human BM-MSCs when 
cultured with the aforementioned factors developed neuronal morphology [62]. In terms of 
marker expression neuron-specific enolase (NSE), NeuN and GFAP increased when cultured 
with EGF and HGF but not EGF alone, implying EGF does not induce neuronal differentiation 
[62]. The lack of bFGF could explain why GFAP expression was reported.  
Supporting the requirement of bFGF is a study using 10ng/ml bFGF, 10ng/ml EGF and 1ng/ml 
platelet derived growth factor (PDGF) [66]. With morphological changes after 2 weeks and 
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up to 3 months [66]. After 5 weeks NSE, βIII-tubulin, NF-M, MAP2 and Tau  expression 
increased, being confirmed  by immunofluorescence, but  GFAP  was not detected [66].  
Other neuronal differentiation protocols include chemical use, such as the method utilised 
by Woodbury et al [63] where MSCs were cultured with dimethylsulfoxide (DMSO), 
butylated hydroxyanisole (BHA) and β-mercaptoethanol (BME). Neurological morphology 
was observed in 80% of BM-MSCs and confirmed with nestin staining, although BM-MSCs 
matured neurologically nestin expression decreased [63]. NeuN, NF-M, Tau, NSE were also 
expressed [63]. More recently the effect of BME alone on neuronal differentiation of rat BM-
MSCs has been investigated [67]. 100 µM of BME induced morphological changes but not at 
higher concentrations (5mM and 10mM). Although BM-MSCCs were pre-induced with 
10ng/ml bFGF. Furthermore, NF and NSE expression was confirmed after 2 and 3 weeks of 
culture, being expressed most highly when culture conditions contained 400µM of BME [68]. 
The effect of BME is supported as mouse BM-MSCs have been induced, displaying neuronal 
morphology and NeuN expression [67]. Interestingly, cryopreservation of BM-MSCs does not 
affect their neuronal potential [61]. BM-MSCs were cultured and chemically induced 
(including DMSO) to express NSE and nestin post-cryopreservation [61]. 
Pre-induction by bFGF (10ng/ml) has been repeated, although alongside DMSO, BHA and 
forskolin [69]. Rat BM-MSCs were pre-treated with bFGF for 24 hours before culture with 
10ng/ml bFGF, 2% DMSO, 100µmol/L BHA and 10µmol/L forskolin [69]. Morphological 
changes were observed in 95% of cells by 24 hours post-treatment and nestin expression 
detected, declining over time [69]. NF expression increased to 98.5% in treated BM-MSCs 
and GFAP was not detected, implying neuron-like differentiation and not glial [69]. However 
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using both cytokine and chemical induction complicates the matter as to which conditions 
are required for neuronal differentiation. In particular when the range of media supplements 
is large, say bFGF, hEGF, brain-derived neurotrophic factor (BDNF), fibroblast growth factor 8 
(FGF-8), IBMX and  dibutyryl cyclic adenosine monophosphate (dbcAMP) [70]. Although by 
day 6 neuronal morphology was observed in 66% of BM-MSCs and expression of numerous 
neural markers was observed (GFAP, GalC, Nurr1, Tau, NF, NeuN, nestin and βIII-tubulin) 
[70] so such as shotgun approach may have its advantages.  
Another approach to induce neurogenic differentiation is co-culturing BM-MSCs. When co-
cultured with human foetal neural cells human BM-MSCs displayed neural morphology and 
NSE expression, which did not occur within control samples without co-culture [71]. Other 
neural products co-cultured with BM-MSCs include cerebrospinal fluid (CSF), although bFGF 
and EGF was also utilised [72]. CSF increased the number of neural-like cells and reduced the 
culture period [72]. Retinal pigment epithelial cells, when co-cultured among  human BM-
MSCs, also generated neuronal differentiation, [73] with expression of nestin, GFAP and NSE. 
Thus cellular contact and support of cells within the in vivo microenvironment is important 
for neural differentiation. 
Apart from previously mentioned chemicals and cytokines other molecules and compounds 
have been investigated to induce neuronal differentiation. One approach takes into account 
epigenetic modification [74]. With mouse BM-MSCs being pre-treated with bFGF and EGF 
before culture with hypomethylating agent 5-aza-2’-deoxycytidine (5azadC) or histone 
deacetylase inhibitor TSA (trichostatin A). Nestin postitive neurospheres and both neuronal 
and glial-like morphology was observed [74]. With a follow up study confirming neuronal 
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differentiation through marker expression and the secretion of BDNF and glial cell derived 
neurotrophic factor (GDNF), by induced BM-MSCs [75]. Other compounds include Fasudil 
hydrochloride [76], a Rho kinase inhibitor, which induced expression of Notch 1, NF-M, GFAP 
and nestin. Radix-astragali, a Chinese medicine, induced nestin up-regulation, alongside 
GFAP, NSE and MAP-2 [77]. Finally the small molecule LY294002, a PI3K/AKT pathway 
inhibitor increased neural-like cells [78]. However, the use of such varied compounds 
requires further investigation into their efficiency and reproducibility.   
Another method generating interest involves increasing the intracellular concentration of 
cAMP. An early study discovered 25% of MSCs expressed vimentin and NSE and were 
neuron-like after 6 days of culture with dbcAMP and isobutylmethylxanthine (IBMX), both 
increase cAMP levels [17]. However, other neural markers were not expressed; namely NF-
M, MAP-2, Tau and GFAP. Supporting the effect of cAMP, an increase in GFAP, TH and MAP-
2 was observed when BM-MSCs were cultured with 5µM cAMP, 5µM IBMX and 25ng/ml 
nerve growth factor (NGF) [59].  
Producing neuron-like cells in terms of morphology and surface marker expression is only 
one aspect of neuronal differentiation, as cells have to be functional. In this respect an early 
achievement was the response obtained to depolarising stimuli by induced neurons, by 
Kohyama et al [79]. Furthermore, bFGF induced mouse BM-MSCs responded to dopamine, 
glutamate and veratridine (voltage-gated Na+ channel agonist) by producing an intracellular 
calcium influx [64]. Action potentials have also been exhibited through whole-patch 
clamping of human BM-MSCs [80]. Although these functionality studies are promising and a 
step forward more investigation is required.  
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Different methods have been attempted in producing neuronal cells from BM-MSCs, in 
particular the effects of chemical compounds and cytokine growth factors. However, there is 
variation within the use of neuronal markers and which were positively or negatively 
expressed. Thus, further work is required in an attempt to find the ideal protocol. 
Standardising methodology would aid in achieving this goal. Some of the variation in neural 
marker expression could be due to species or donor variation [81]. As the expression of NSE, 
NF-L, TH, Nurr1 and nestin varied between four donors [81].  
2.2.2 Dental Tissue 
Although BM- MSCs have been widely acknowledged to show neurogenic potential, there is 
the hypothesis dental derived MSCs ‘may possess a greater propensity for neuronal 
differentiation and repair’ due to their cranial neural crest cell origin [14, 18, 20]. As such 
research has attempted to investigate the neuronal differentiation potential of dental 
derived MSCs, with some studies comparing their findings against BM-MSCs.  
One recent study compares the differentiation potential of MSCs between human DPSCs and 
human BM-MSCs [22] (see table 2.2). DPSCs were isolated from adult 3rd molars and DP pulp 
enzymatically digested, whereas BM-MSCs were obtained from the iliac crest and separated 
by Ficoll-histopaque gradient centrifugation. Both DPSCs and BM-MSCs were cultured for 3 
days and MSCs selected on plastic adherence ability [22]. Both groups displayed fibroblast 
morphology and expressed MSC markers [16]. However, CD106, a vascular cell adhesion 
molecule, was expressed at lower levels in DPSCs, compared to BM-MSCs, 1.90% and 13.91% 
respectively (flow cytometry data). Also the endothelial cell lineage marker CD146 was lower 
in DPSCs, 46.16% compared to 87.63% in BM-MSCs (flow cytometry data). Although overall, 
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DPSCs show as much potential as MSCs as BM-MSCs. Furthermore, differentiation 
capabilities of DPSCs were confirmed as similar to BM-MSCs, with formation of adipogenic, 
osteogenic and chondrogenic lineages [22]. The neurogenic potential was evaluated by 
driving MSCs down a neural differentiation pathway by supplementing culture medium with 
0.5mM IBMX, 10ng/ml BDNF, EGF, bFGF and neural stem cell proliferation supplements. 
After 3-5 days of culture, neural marker expression was determined with immunofluorescent 
staining, with DP-SCs being positive for c-fos, βIII-tubulin, NSE, MAP-2 and NF-H. In addition, 
neural progenitor markers nestin, vimentin and tenascin along with GFAP were expressed 
[22]. With NF-H, NF-L NSE, nestin and βIII-tubulin expression confirmed by RT-PCR analysis.  
The neuron-like cells derived from DPSCs formed a range of morphology’s, from bipolar cells 
to branched multipolar cells and they report immunohistochemistry staining during 
differentiation intensified, indicating a continuous progressive differentiation pathway was 
stimulated [22]. Furthermore, DPSCs displayed a stronger expression of BMP-2, which is 
involved in neurogenesis, than BM-MSCs. Overall Karaoz et al [22] show  DPSCs are a valid 
source of MSCs and comparable to BM-MSCs in terms of marker expression and 
differentiation potential. Also DPSCs show a capacity to differentiate into neural-glial cells in 
vitro and combined with their increased proliferation rate over BM-MSCs may be a MSC 
population source for the treatment of neurological diseases. However, as promising as this 
is, much of the BM-MSC data is not presented and a direct comparison between the two 
sources not always evident. Another slight inconsistence is the use of RT-PCR when studying 
osteogenic differentiation but only using PCR for neurogenic differentiation. It would be 
beneficial to have quantitative data for neurogenic differentiation to allow a direct 
comparison between both cell types. Although neural-glial cell types were obtained, 
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morphology varied greatly. Thus the differentiation protocol lends itself to produce a 
heterogeneous population of neural cells, rather than one specific type, which is required to 
overcome a variety of neurological diseases. In addition, the differentiation protocol was 
very short, only being 3-5 days, whereas other studies have a longer period. This could imply 
neuronal-like changes are merely artefacts of the quick protocol, and if neurogenic 
differentiation medium were to be removed the MSCs may defer back to their original 
phenotype.  
Supporting the neurogenic potential of dental derived tissue is a study by Nourbakhsh et al 
[10] (see table 2.2), although SHEDs were the MSC source. Again enzymatic digestion was 
the method of isolation and MSCs were selected on plastic adherence, along with 
morphological appearance and alkaline phosphatase staining. MSC marker expression of 
Stro-1 and CD146 was confirmed at 96.5+/-1.8% and 49.0+/-8.9% respectively (flow 
cytometry data), comparable to the expression level of 46.16% for CD146 by Karaoz et al 
[22]. Other MSC markers displayed positive expression; CD106, CD166, CD90, and negative 
expression for CD31, CD34 and CD45. Thus confirming SHEDs conform to MSC criteria [16]. 
However, neurogenic differentiation followed a different protocol by culturing the SHEDS in 
neurobasal medium supplemented with 1% ITS and 100ng/ml bFGF for five days. Following 
this the 100ng/ml bFGF was continued with the addition of 10ng/ml FGF-8 and 100ng/ml 
SHH, for 5 days. Neuron-like cells were produced showing a range of morphology’s, again 
from simple bipolar to large branched multipolar cells [10]. To further validate these changes 
the neural differentiation medium was replaced with unsupplemented medium and the vast 
majority of SHEDs maintained neuronal morphology. Supporting neuronal differentiation 
achievement is neural marker expression; Nestin, neural cell adhesion molecule (NCAM), β-
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III tubulin, NeuN, Tau, Tyrosine Hydroxylase (TH) and GFAP, via both immunofluorescence 
and flow cytometry, after 10 days of neuronal differentiation [10](see figure 2.1). Expression 
was confirmed with RT-PCR and western blot analysis. Overall, results support the 
hypothesis that SHEDs can be induced via neurogenic differentiation medium conditions to 
form cells with a neural morphology, surface marker expression and phenotype [10]. 
Although the role of each induction factor, bFGF, SHH and FGF8, is known within 
neurogenesis, the actual neural induction procedure itself was novel. Thus, providing a 
successful method of inducing neural-like cells from a population of MSCs, namely SHEDs, 
due to the longer differentiation protocol. In addition quantitative  experimental evidence is 
presented, but overall marker expression was not as extensive as Karaoz et al [22]. In 
addition, not all potential differentiation lineages were verified.  
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Figure 2.1 Dental derived mesenchymal stem cells neurogenic potential 
(A) Morphological changes of human DPSCs induced by PKC and cAMP, after 10 days of 
differentiation. White arrow heads show multipolar morphology. Black arrows show bipolar 
morphology. Scale bar = 100 μm. Taken from Király et al[3]. (B) Human DPSCs neurosphere 
formation induced by bFGF  (20 ng/ml)and EGF (20ng/ml). i) control ii)EGF only iii) bFGF only 
iv) EGF and bFGF. Scale bar = 200 μm Taken from Osathanon et al [6]. (C) Expression of βIII-
tubulin (i) and nestin (ii) in undifferentiated dental follicle cells (DFC). Taken from Völlner et 
al [8]. (D) Expression of neuronal markers in undifferentiated and differentiated human 
SHEDs, induced by bFGF, FGF8 and SHH. Taken from Nourbakhsh et al [10]. (E) Expression of 
NSE (i) and PANneurofilament (ii) in differentiated DFCs, induced by bFGF and EGF. Taken 
from Völlner et al [8]. (F) Functional analysis of differentiated (D) and non-differentiated 
(ND) human DPSCs via Na+ currents in response to voltage steps. Neural differentiation 
induced by EGF and bFGF. Taken from Arthur et al [14].  
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SHEDs have also been studied in direct comparison to DFCs, for neural differentiation 
potential [82]. Both groups were cultured for 7 days in four different serum replacement 
mediums, each being a supplemented Neuralbasal Medium. NDM I with G5 and Neural Stem 
Cell Supplement ; NDM II with N2, 20µg/ml EGF and 20µg/ml FGF-2; NDM III with B27 
NeuroMix, EGF and bFGF; NDM IV with B27 NeuroMix. MSC phenotype was tested with Stro-
1 and notch-1 marker expression with 27% and 35% Stro-1 expression for SHEDs and DFCs 
respectively and over 90% for Notch-1 in both groups. In addition, both groups expressed 
CD166, DC146, CD105, CD73 and CD13 and therefore display similar MSC expression profiles, 
although marker expression was not quantified. Neurogenic differentiation resulted in a 
decrease in cellular proliferation in both SHEDs and DFCs, when cultured with NDM I, NDM 
III and NDM IV. However, morphological changes varied between cell groups and media 
composition, with neurospheres observed in NDM II and NDM IV but only for SHEDs. Also 
DFCs only showed ‘neurite-like extensions’ in NDM I and not the other culture mediums. In 
terms of neural marker gene expression the results varied between each group with one 
main difference being upregulation of GFAP in SHEDs for NDM I, NDM II and NDM III, up to a 
12 fold increase compared to GAPDH. Yet no or relatively low GFAP expression rates for 
DFCs. Although, nestin, βIII-tubulin and NF-M displayed similar up regulation in both SHEDs 
and DFCs, for all four media types. Morsczeck et al [82] report both groups express MSC and 
neural SC markers, supporting the neural crest origin of dental derived SCs. Yet, also 
highlighting the difference between SHEDs and DFCs, particularly expression or lack of 
expression of GFAP, which indicates SHED have the potential to become glial-like cells as 
well as neurons whereas DFC do not display glial potential [82]. Thus the task of defining 
each subset of dental cells is vital to the possible future use of such tissues clinically. 
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Furthermore, the great variation in neuronal morphology and gene expression between both 
the culture mediums and cell sources displays the need for further investigation into exactly 
which factors are required to promote neurogenic differentiation of a particular MSC source.  
Neural markers expression and morphological changes are just one step in confirming the 
neurogenic potential of dental tissue, the next step is to obtain functional neurons, as 
hypothesised by Arthur et al [14] (see table 2.2). DPSCs were extracted from 3rd molars via 
collagenase digestion and neurogenic differentiation was obtained under in vitro culturing 
conditions. Although two different neural inductive media’s were used; Neurobasal A media 
containing 20ng/ml EGF and 40ng/ml bFGF, whereas Media B culturing conditions varied. 
With a week of media A, a week of 50:50 DMEM with F12 media containing insulin 
transferring sodium selenite supplement, 40ng/ml bFGF and a final week of week 2 media 
but with 0.5µM RA [14]. After 3 weeks culture in both conditions, DPSCs expressed neuronal 
morphology of both sensory bipolar neurons and motor stellate neurons. Neurological 
markers, NCAM, β-III tubulin, NF-M and NF-H were expressed significantly higher by DPSCs in 
both media conditions, with the exception of nestin which was expressed at similar rates to 
the control media [14]. Furthermore, RT-PCR analysis supports the findings, with nestin 
expression decreased and NF-M and NF-H increased four and sevenfold respectively. With 
NF-M and NF-H being expressed in mature neurons and sequentially; NF-M, a component of 
the axon cytoskeleton expressed in myelinated neurons, being expressed prior to NF-H [14]. 
Taken with a reduction of proliferation rates the findings suggest both media conditions 
induced DPSCs into mature neurons [14]. In addition, Arthur et al investigated functional 
neuronal properties of induced DPSCs through electrophysiology patch clamping and it was 
observed differentiated DPSCs produced a large, fast, inactivating inward current and 
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express voltage gated sodium channels [14]. Whereas non differentiated DPSCs and both 
differentiated and non differentiated human foreskin fibroblasts showed no such effect (see 
figure 2.1), implying DPSCs differentiate into functionally active neurons when induced by 
appropriate culture conditions [14]. Furthermore, injection of DPSCs into a developmental 
avian embryo model shown the capability of DPSCs to respond in vivo to neuronal 
differentiation stimuli [14]. Unlike some studies Arthur et al go beyond marker expression 
and neural morphology but confirm DPSCs neurogenic potential through electrophysiology 
experiments and in vivo implantation, although not extensive, a valid and required step to 
obtain functional neurons from DPSCs. However, not presented is data confirming the DP 
cells as MSCs [16].  
 
Table 2.2 Summary of dental tissue MSC neurogenic differentiation studies. With type of 
MSC used and how they were extracted. Along with MSC markers and multilinerage 
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One common factor in the above studies [10, 14, 22] is the inclusion of bFGF (20-100ng/ml). 
The effect of both bFGF and EGF on neuronal differentiation of DPSCs was recently studied 
specifically [6] (see table 2.2). DPSCs were confirmed as MSCs via expression of CD44, CD73 
and Stro-1, along with fibroblast-like morphology. As for neurogenic potential neurosphere 
formation was observed early at day 1 and had grown by day 7. In addition, secondary and 
tertiary neurosphere formation was possible from isolated primary neurosphere cells [6]. 
Following plating onto collagen IV treated plates DPSCs formed neural-like cytoplasmic 
processes and were positive for βIII-tubulin. With expression of Sox2, Sox9, and NF displayed 
by neurospheres. With regards to the effect of bFGF and EGF, the addition of bFGF on its 
own or bGFG with EGF increased neurosphere size (see figure 2.1) with a larger percentage 
being ‘greater than 100µM’ in size. Furthermore, expression of Sox2 and βIII-tubulin 
increased, although this increase was not quantified and purely based on PCR rather than 
RT-PCR [6]. Once neurospheres were cultured as a monolayer a similar increase in mRNA 
levels was observed, for So2, Sox9, βIII-tubulin. bFGF application produced a neural-like 
morphology, compared to MSC morphology for the control group [6]. These effects were 
inhibited by FGFR inhibitors, thus highlighting the importance of bFGF for inducing 
neurogenic differentiation. However, their [6] evidence of neuronal differentiation was 
limited to a small number of neural markers and the analysis of further markers would 
produce stronger evidence to support their conclusion.  
More support for bFGF and EGF mediating neural differentiation in dental tissues, comes 
from DFCs [8] (see table 2.2). Interestingly, without neural induction DFCs displayed 
expression of early neural markers nestin and β-III tubulin (94%+-4.7 SEM) and formed 
neurosohere-like cell clusters, positive for said markers, when cultured with B27 
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supplement, EGF and bFGF. DFCs, when cultured on Poly-L-lysine displayed neurosphere-like 
cell clusters for each of the different supplemented mediums. With two mediums containing 
EGF and bFGF and the other containing no growth factors but B27 and RA [8]. Thus 
supporting the involvement of EGF and bFGF in neuronal differentiation but also the 
inclusion of RA. Furthermore peak expression of neural markers βIII-tubulin, nestin, NF and 
Map-2 was observed with neural medium I, which contained higher levels of bFGF 
(500µg/ml) and EGF (500ng/ml). In addition, expression of GAL and TAC1 increased in the 
presence of all three neural mediums. Suggesting neurospheres induced by bFGF, EGF and 
RA contain neural precursors or small/intermediate size neurons [8]. Finally, further 
differentiation of neurospheres obtained via the use of neural medium I showed DFCs 
displaying neural morphology and expressing NSE and NF.  
Neurospheres have also been generated from rat DPSCs via the use of bFGF (20ng/ml) and 
EGF (20ng/ml) [83] (see table 2.2). In particular bFGF is the important factor as the diameter 
of neuropshere’s induced with only EGF were similar to control levels, without growth 
factors. A significant increase in neurosphere diameter size was observed through addition 
of bFGF, yet no comparable difference between sphere size when EGF was added alongside 
bFGF. Neurospheres expressed neural markers nestin and CD81 [83]. In addition, βIII-tubulin 
and S100 positive cells were reported within the neurospheres, suggesting the potential of 
rat DPSCs to differentiate into both neural and glial like cells. bFGF also effected 
neurosphere expansion by significantly increasing the number of spheres, whereas other 
growth factors had no effect [83]. However, the data is still not conclusive as only a small 
number of markers were used and the neurospheres generated were limited in their self-
renewal and suggested to be characterised as ‘progenitor cells’ rather than ‘stem cells’  [83].  
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2.3 Concluding Remarks 
Although bFGF and EGF have been predominately used, other factors have produced more 
specific neural differentiation, such as the application of 5ng/ml transforming growth factor 
β (TGF-β) to mouse DFPCs promoting glial-like differentiation [84]. Whereas, PKC and cAMP 
activators aided neural differentiation into functionally active neurons, along with treatment 
of bFGF [3] (see figure 2.1). Yet overall, much of the evidence and research into inducing 
neuronal differentiation does use bFGF and EGF, thus leading to the conclusion both are 
important factors required. However, the addition of factors such as FGF-8 [10], SHH[10] and 
RA [8, 41] aid neural differentiation, alongside bFGF and EGF. Choosing which factors to 
induce differentiation is only part of the problem as other variables include the quantity of 
factor required to produce optimum differentiation, as numerous concentrations of bFGF 
and EGF have been used (20-100ng/ml). Another factor requiring further investigation is the 
culture time required to produce neural differentiation as this various between studies with 
some presenting evidence in as few as 3-5 days [22] and others longer, up to 3 weeks [10, 
14]. Though longer culture periods seem more likely as a requirement. In addition, often a 
snap shot of gene expression levels on a particular day is presented as support of neurogenic 
differentiation. Yet, as differentiation is dynamic it would be beneficial to produce a time 
course, taking samples at regular interviews and examining neural marker gene expression 
levels. Such an approach could display results showing various markers changing over the 
culture period, such as early neural markers (particularly nestin) peaking early and declining 
as markers of mature neurons increase. Another area requiring further development is the 
production of functional neurons as most studies only investigate expression of neural 
markers and morphological change. In particular there has been criticism with regards to the 
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validity of neural-like processes used to support claims for successful neuronal 
differentiation [85]. Rat BM-MSCs were pre-treated with bFGF but induced with DMSO, BHA, 
forskolin and valproic acid (VPA). It was observed that 73%  of BM-MSCs formed neural-like 
projections but these were easily reversed by removal of inducing factors [85]. With similar 
neural-like projections for fibroblasts and investigation into actin, it was concluded the 
mechanism causing neuronal-like morphology was due to actin breakdown and cytoplasm 
retraction [85]. In addition, DMSO and BME neural induction was observed within fibroblasts 
and neural-like processes where due to cytoskeleton breakdown [86]. Although such reports 
have been counteracted where live cell microscopy confirmed morphological changes as 
being due to ‘active and dynamic processes involving outgrowth and motility of cellular 
extensions’ [87]. Yet the debate about the validity of the neural-like projections does need 
acknowledging and highlights the importance of functional studies to support true neuronal 
differentiation.    
As for which source is more appropriate for neuronal differentiation, BM-MSCs or dental 
derived MSCs, still needs to be explored. However, the field is looking promising for dental 
MSCs as under similar conditions to BM-MSCs DPSCs display neuronal differentiation, using 
both chemical induction and cytokines induction. Morphological changes and the up-
regulation of many neuronal markers have been reported in both groups. One factor which 
implies dental MSCs may be more useful is the increased proliferation rates, which are 
reported as being higher in DPSCs and SHEDs when compared to BM-MSCs [5, 15] (figure 
1.4), in addition to the relative ease of extraction and accessibility of dental derived MSCs. 
Although, before definite conclusions can be drawn, further experimentation is required, for 
instance the effect of co-culturing dental MSCs in similar conditions to BM-MSCs [71-73]. 
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Also more direct comparisons between the two groups and more comprehensive evaluation. 
So that populations are thoroughly defined as MSCs through marker expression and multi-
lineage potential before neuronal differentiation and that differentiation evidence uses 
multiple neural markers, before finally establishing the functionality of neuronal-like cells.   
3 MSCs Neurological Potential in the Clinic 
As outlined above neural differentiation of MSCs in vitro has been investigated. The reason 
for such interest is due to MSCs potential in combating numerous neurological diseases, with 
many reviews on the subject [35, 37, 46, 88-92]. In particular as MSCs are relatively 
accessible, bypass problems with the immune reaction (when autologous) and can be 
expanded in vitro [37]. MSCs have potential in Parkinson’s disease, Huntington’s disease, 
spinal cord injury and amyotrophic lateral sclerosis, with a summary of each field below.  
Parkinson’s disease (PD) is a progressive degenerative neurological disorder [93] due to loss 
of dopaminergic neurons from the nigrostriatal pathway [93], with the clinical focus on 
replacing lost dopaminergic neurons. Dental pulp cells have been shown to secrete NGF, 
BDNF and GDNF, which enhanced the survival of embryonic dopaminergic (DA) neurons [94], 
MSCs also protect DA neurons from neurotoxin 6-OHD [94]. BM-MSCs also display protective 
effects from neurotoxins, in this case increasing TH expression and reducing cell damage 
against MPP [95]. Supporting this TH expression increased when ventral mesencephalic cells 
were co-cultured with BM-MSCs [96] and alpha-synuclein was reduced using the 6-OHDA 
induced model of PD, again with BM-MSC co culture. [97]. MSCs have a supporting role for 
DA neurons but they can be induced into DA neurons through use of fibroblast growth 
factors and SHH up-regulating TH [98]. Though other approaches  focus on generating 
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supportive astrocyte-like cells, through cytokine induced differentiation [99]. Human BM-
MSCs once differentiated produced GDNF, NGF and BDNF and when transplanted into a rat 
model improvement in motor function was observed [99]. Although these findings are 
refuted as undifferentiated and pre-differentiated BM-MSCs did not display further 
differentiation nor neurogensis when transplanted into 6-OHDA rats [100]. Alternatively 
lentiviral delivery has been utilised to increase TH expression [101]. So overall the field of 
MSCs in improving PD is promising but requires further investigation.   
Neurotrophic secretion has been investigated for treating Huntington’s disease (HD), 
another neurodegenerative disorder impairing movement and cognition [88, 102]. BM-MSCs 
from HD patients were differentiated and displayed secretion of neurotrophic factors (NTF) 
and when transplanted into rats produced NTFs and behavioural improvement [103]. A 
supportive role for MSCs is again apparent as mice transplanted with BM-MSCs displayed 
improved motor function through NTF support [104]. Such findings have been reproduced 
and summarised by Olson et al [102], but overall transplanted BM-MSCs improve motor 
function and reduce lesion volume [102]. Although the next step would be to pre-
differentiate the MSCs prior to implantation to determine if further improvement is gained.  
Amyotrophic lateral sclerosis (ALS) also results in neuronal loss and is neurodegenerative, 
though affecting motor neurons [88]. One novel development used encapsulated MSCs and 
injection into a ALS mouse model [105]. Prior to injection human BM-MSCs were 
immortalised and transfected to produce glucagon-like peptide 1, known for its 
neuroprotective effects [105]. Mice treated with encapsulated MSCs survived for longer, 
displayed improved rotarod performance and motor function [105]. Whereas other 
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approaches focus on neuroprotection and neurotrophic secretion [106]. BM-MSC injected 
mice displayed improved motor function, although MSC selected cells did not express GDNF, 
whereas whole bone marrow extracts did [106]. MSC transplantation for ALS has been under 
phase I clinical trials but did not show improvement and only confirmed the safety of such 
procedures [107].  
One other area where MSCs show potential, due to their supportive neurotrophic releasing 
ability when differentiated, is within treating spinal cord injury. With early work from DPCs 
displaying release of BDNF, NGF and GDNF and trigeminal neurite extension, when co-
cultured with trigeminal neurons [108]. Furthermore, DPC grafts in a model of spinal cord 
injury improved the number of surviving motor neurons [108]. Expanding upon this DPSCs, 
once implanted, stimulate axon growth in an avian model [109]. GFP tagged DPSCs were 
injected into an embryo and after 48 hours collected around the trigeminal ganglion, where 
increased axon growth was observed towards the DPSCs [109]. Such techniques could be 
beneficial in stimulating axonal growth in spinal cord injury and promote neurogenesis. In 
vivo transplantation of BM-MSCs also improved spinal cord injury [110].  Though BM-MSCs 
were pre-differentiated with RA and infected with an adenoviral vector to increase 
neurotrophin-3 expression prior to injection. Implantation had a number of effects; 
promoting axon repair, increasing the surviving neurons and improving motor function 
[110].  
Although MSCs show promise for future therapy in treating various neurological diseases 
further experimentation is required. In many conditions the supportive role of MSCs is 
shown as having a beneficial effect, often from the implantation of undifferentiated MSCs. 
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Yet much research has been undertaken into in vitro differentiation so comparing the post 
transplantation effects between undifferentiatied and predifferentiated MSCs could be 
beneficial, in determining whether predifferentiation is required or not. Predifferentiated 
DPSCs can intergrate into the rat brain and be studied electrophysiologically [111]. 
Furthermore, comparing sources of MSCs in transplantation, would be beneficial as it may, 
be observed for a particular disorder the use of DPSCs improves functionality more than BM-
MSCs. As a whole, the field is promising and the idea of autologous transplantation is very 
appealing. Eventually, when one is diagnosed with a disorder their own MSCs could be 
cultured and transplanted back into themselves, providing a clinical improvement. Although 
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MSCs are pluripotent and have a self-renewing ability. They were first isolated from bone 
marrow [11] but have since been isolated from other tissues. In particular, dental tissues 
where a number of populations have been isolated and characterised, namely; DPSC [12],  
SHED [15], SCAP [52], PDLSC [55] and DFPC [56]. MSCs are known for their fibroblast-like 
spindle morphology and their multi-lineage differentiation potential of adipogenic, 
osteogenic and chrondrogenic cell types. However, MSCs also display early neural markers, 
such as nestin, and can be induced into neuronal-like cells, through the use of chemicals and 
cytokine growth factors, including bFGF. With both bone marrow derived and dental tissue 
MSCs displaying this neurogenic ability. Due to this potential much interest has been 
generated in terms of treating neurological disease. With research involving MSCs in PD, HD, 
ALS and spinal cord injury showing promise for future MSC derived therapy. Though this field 
is still in it’s infancy and it remains to be ascertained if any particular source of MSC shows 
more promise over other sources., although dental derived MSCs are desirable candidates 
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